タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	磁気共鳴スペクトルの医学応用 ―MRSの基礎から臨床まで―
出版社	インナービジョン
発行日	2012-03-16
著者	成瀬昭二(監著) 梅田雅宏(編著) 原田雅史(編著) 田中忠蔵(編著)
ISBN	9784902131222
ページ数	304
版刷巻号
分野	臨床医学：一般画像/超音波
閲覧制限	未契約

生体の代謝物質情報を非侵襲的に得ることができる MRS(MR spectroscopy)。高磁場装置の普及や技術革新を機に、改めてMRSへの期待が高まるいま、基礎から臨床までをわかりやすく解説します。MRSの発展と普及は本書から。

目次

表紙
閲覧
序
P.3閲覧
巻頭カラー口絵
P.5閲覧
目次
P.13閲覧
略語一覧表(本文中は略語のみ記載)
P.26閲覧
概論
P.31閲覧
第1章 MRSの基礎
P.35閲覧
- 1-1 MRSの原理
- 1-2 NMRスペクトルから得られる情報
- 1-3 NMR/MRSのハードウエア
- 1-4 より良いスペクトルを計測するために
- 1-5 MRSデータ処理
- 1-6 局在MRSの方法
- 1-7 MRSデータ発表の留意点
- 1-8 MRSに必要な代謝知識
第2章動物実験におけるMRS
P.95閲覧
- 2-1 脳疾患モデルの実験MRS
- 2-2 腫瘍の実験MRS
- 2-3 筋肉の実験MRS
- 2-4 肝臓・心臓の実験MRS
- 2-5 実験MRSのための周辺技術-臓器灌流法と灌流臓器の生理学モニタ
- 2-6 実験MRSのための周辺技術-動物の設定および生理学モニタ
- 2-7 動物実験用MRI
第3章 MRSの臨床応用
P.159閲覧
- 3-1 MRSの臨床応用の現状と問題点
- 3-2 脳のMRS
- 3-3 心臓のMRS
- 3-4 肝臓のMRS
- 3-5 骨格筋のMRS
- 3-6 前立腺の1H-MRS
- 3-7 子宮・卵巣のMRS
- 3-8 乳房のMRS
第4章高度な技法のMRS
P.261閲覧
- 4-1 多核種MRS
- 4-2 二次元MRS
- 4-3 選択照射を用いるスペクトル編集法
おわりにあたり-今後の可能性
P.286閲覧
著者一覧
P.287閲覧
索引
P.293閲覧
奥付
閲覧

参考文献

表紙

P.33 掲載の参考文献

1) Purcell, E.M., Torrey, H.C., Pound, R.V.:Resonance absorption by nuclear magnetic moments in a solid. Phys Rev 69:37-38, 1946.

2) Bloch, F., Hansen, W.W., Packard, M.E.:Nuclear induction. Phys Rev 69:127, 1946.

3) Odebald, E., Lindstrom, G.:Some preliminary observations on the proton magnetic resonance in biological samples. Acta Radiol 43:469-476, 1955.

4) Saunders, M., Wishnia, A., Kirkwood, J.G.:The nuclear magnetic resonance spectrum of ribonulease. J Am Chem Soc 79:3289-3290, 1957.

5) Ernst, R.R., Anderson, W.A.:Applications of Fourier transform spectroscopy to magnetic resonance. Rev Sci Instrum 37:93-102, 1966.

6) Moon, R.B., Richard, J.H.:Determination of intracellular pH by 31P magnetic resonance. J Biol Chem 248:7276-7278,1973.

7) Hoult, D.I., Busby, S.J., Gadian, D.G., et al.:Observation of tissue metabolites using 31P nuclear magnetic resonance. Nature 252:285-287, 1974.
pubmed

8) Ackerman, J.J.H., Grove T.H., Wong G.G., Gadian, D.G., etal.:Mapping of metabolites in whole animals by 31P NMR using surface coils. Nature 283:167-170, 1980.

9) Ross, B.D., Radda, G.K., Gadian, D.G., et al.:Examination of a case of suspected McAedle's syndrome by 31P nuclear magnetic resonance. N Eng J Med 304:1338-1342, 1981.

10) Cady, E.B., de L Costello, A.M., Dawson, M.J., et al.:Non-invasive investigation of cerebral metabolism in new born infants by phosphorus nuclear magnetic resonance spectroscopy. Lancet 321:1059-1062, 1983.

11) Bottomley, P.A., Foster, Th.B., Darrow, R.D.:Depth-resolved surface coil spectroscopy (DRESS) for in vivo 1H, 31P and 13C NMR. J Magn Reson 59:338-342, 1984.

12) Ordidge, R.J., Connelly, A., Lohman, J.A.B.:Image-selected in vivo spectroscopy (ISIS); A new technique for spatially selective NMR spectroscopy. J Magn Reson 66:283-294,1986.

13) Luyten, P.R., Marien, A.J.H., Sijtsma, B. et al.:Solvent suppressed spatially resolved spectroscopy; An approach to high-resolution NMR on a whole-body MR system. J Magn Reson 67:148-155, 1986.

14) Frahm, J., Merboldt, K.D., Haenicke, W.:Localized proton spectroscopy using stimulated echoes. J Magn Reson 72:502-508, 1987.

15) Kimmich, R., Hoepfel, D.:Volume-selective multipulse spin-echo spectroscopy. J Magn Reson 72:379-384, 1987.

16) Brown, T.R., Kincaid, B.M., Ugurbil, K.:NMR chemical shift imaging in three dimesions. Proc Natl Acad Sci USA 79:3523-3526, 1982.

17) Segebarth, C.M., Baleriaux, D.F., Luyten, P.R. et al..:Detection of metabolic heterogeneity of human intracranial tumors in vivo 1H NMR spectroscopic imaging. Magn Reson Med 13:62-76, 1990.
pubmed

序

P.43 掲載の参考文献

1) ファラー, ベッカー:パルスおよびフーリエ変換NMR. 吉岡書店, 1979.

2) スリクター, C.P.:磁気共鳴の原理. 益田義賀訳, シュプリンガー・ジャパン, 1998.

3) Akitt, J. W.:NMR 入門. 広田穣訳, 東京, 化学同人, 1988.

4) Akasaka, K.:Longitudinal relaxation of protons under cross saturation. J Magn Reson 45:337-343, 1981.

5) Derome, A.E., 竹内敬人:化学者のための最新NMR概説-よりよいスペクトルを得るための実験法と考え方. 野坂篤子訳, 化学同人, 1992.

6) Aue, W.P., Bartholdi, E., Ernst, R.R.:Two-dimensional spectroscopy ; Application to nuclear magnetic resonance. J Chem Phys 64:2229, 1976.

P.51 掲載の参考文献

1) Abraham,R.J., Loftus, P., Fisher,J.:Introduction to NMR Spectroscopy. John Wiley & Sons, 1992.

2) 西口栄子, 梅田雅宏:31P-NMR におけるヒト赤血球内における無機燐酸の動向. 日本女子衛生短期大学紀要 7:41-47, 1986.

3) Hennig, J., Pfister, H., Ernst, T., Ott, D.:Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy. NMR Biomed 5:193-199,1992.
pubmed

4) Buchli, R., Ernst, M., Boesiger, P.:Comparison of calibration strategies for the in vivo determination of absolute metabolite concentration in the human brain by 31P MRS. NMR Biomed 7:225-230, 1994.

5) Ernst, T., Kreis, R., Ross, B.D.:Absolute quantitation of water and metabolites in the human brain ; I. Compartments and wate. J Mang Reson Series B, 102:1-8, 1993.

6) Hetherington, H.P., Pan, J.W., Mason, G.F., et al.:Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 36 (1):21-29, 1996.

7) Pirko, I., Fricke, S.T., Johnson, A.J., et al.:Magnetic Resonance Imaging, Microscopy, and Spectroscopy of the Central Nervous System in Experimental Animals. NeuroRx 2 (2):250-264, 2005.
pubmed

8) Kinoshita, Y., Yokota, A.:Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 10 (1):2-12, 1997.
pubmed

9) Wilson, M., Davies, N.P., Grundy, R.G.,et al.:A quantitative comparison of metabolite signals as detected by in vivo MRS with ex vivo 1H HR-MAS for childhood brain tumours. NMR Biomed 22 (2):213-219, 2009.
pubmed

10) de Graff, R.A.:In vivo NMR spectroscopy; Priciples and techniques. John Wiley and Sons, 64-65, 1998.

11) Ward, K.M., Aletras, A.H., Balaban, R.S.:A new class of contrast agents for MRI based on chemical exchange using saturation transfer. J Magn Res 143:79-87, 2000.

12) Gadian, D.G., Radda, G.K., Brown, T.R., et al.:The activity of creatine kinase in frog skeletal muscle studied by saturation-transfer nuclear magnetic resonance. Biochem J 15 (194):215-228, 1981.
pubmed

13) Weiss, R.G., Gerstenblith, G., Bottomley, P.A.:ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc. Natl. Acad. Sci. USA. 102 (3):808-813,2005.
pubmed

14) Chen, W., Zhu, X.H., Adriany, G., Ugurbil, K.:Increase of creatine kinase activity in the visual cortex of human brain during visual stimulation; A 31P magnetization transfer study. Magn Reson Med 38 (4):551-557, 1997.
pubmed

15) Meyer, R.A., Sweeney, H.L., Kushmerick, M.J.,:A simple analysis of the "phosphocreatine shuttle". Am J Physiol 246 (5 Pt 1):C365-377, 1984.

16) Yoshizaki, K., Watari, H., Radda, G.K.:Role of phosphocreatine in energy transport in skeletal muscle of bullfrog studied by 31P-NMR. Biochim Biophys Acta 1051 (2):144-150, 1990.
pubmed

17) Nicolay, K., Braun, K.P., Graaf, R.A., et al.:Diffusion NMR spectroscopy. NMR Biomed 14 (2):94-111, 2001.
pubmed

18) Bito, Y., Hirata, S., Nabeshima, T., Yamamoto, E.:Echoplanar diffusion spectroscopic imaging. Magn Reson Med 33 (1):69-73, 1995.
pubmed

19) Prasad, P.V., Nalcioglu, O.:A modified pulse sequence for in vivo diffusion imaging with reduced motion artifacts. Magn Reson Med 18 (1):116-131, 1991.
pubmed

20) Bito, Y., Hirata, K., Ebisu, T., et al.:Motion Artifact Reduction Using Bipolar Diffusion Gradients in Diffusion-weighted Echo-planar Spectroscopic Imaging, ISMRM proceedings,721, 2010.

21) Hakumaki, J.M., Pirttila, T.R., Kauppinen, R.A.:Reduction in water and metabolite apparent diffusion coefficients during energy failure involves cation-dependent mechanisms; A proton nuclear magnetic resonance study of rat cortical brain slices. J Cereb Blood Flow Metab 20 (2):405-411, 2000.
pubmed

P.61 掲載の参考文献

1) Golay, M.J.E., Rumson, N.J.:magnetic field control apparatus. USP 3:515,979, 1970.

2) Glover, G.H., et. al.:Comparison of linear and circular polarization for magnetic resonance imaging. J Magn Reson 64:255-270, 1985.

3) Chen, C.N., Hoult, D.I, Sank, V.J:Quadrature detection coils-a further √2 improvement in sensitivity. J Magn Reson 54:324-327, 1983.

4) Hayes, C.E., et al.:An Efficient, highly homogeneous radio frequency Coil for whole-body NMR imaging at 1.5 T. J Magn Reson 63:622-628, 1985.

5) Hayes, C.E.:A simplified design procedure for birdcage resonators. Proceeding SMRM 947, 1989.

6) Harpen, M.D.:Harmonic structure of cylindrical imaging coils. Med Phys 17 (4):686-690, 1990.
pubmed

7) Roemer, P.B., Edelstein, WA., Hayes, CE., et al.:The NMR phased array. Magn Reson Med 16:192-225, 1990.
pubmed

8) Hayes, C.E., Hattes, N., Roemer, PB.:Volume imaging with MR phased arrays. Magn Reson Med 18:309-319, 1991.
pubmed

P.75 掲載の参考文献

1) Jehenson, P., Syrota, A.:Correction of distortions due to the pulsed magnetic field gradient-induced shift in B0 field by postprocessing. Magn Reson Med 12 (2):253-256, 1989.

2) Lim, K.O., Pauly, J., Webb, P., et al.:Short TE phosphorus spectroscopy using a spin-echo pulse. Magn Reson Med 32 (1):98-103, 1994.
pubmed

3) Luyten, P.R., Groen, J.P., Vermeulen, J.W., den Hollander,J.A.:Experimental approaches to image localized human 31P NMR spectroscopy. Magn Reson Med 11 (1):1-21, 1989.
pubmed

4) Provencher, S.W.:A constrained regularization method for inverting data represented by linear algebraic or integralequations. Comput Phys Commun 27:213-227, 1982.

5) Provencher, S.W.:Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30 (6):672-679, 1993.
pubmed

6) Kato, T., Tokumaru, A., O'uchi, T., et al.:Assessment of brain death in children by means of P-31 MR spectroscopy; Preliminary note. Work in progress. Radiology 179 (1):95-99, 1991.
pubmed

P.83 掲載の参考文献

1) Ernst, R.R., Bodenhausen, G., Wokaun, A.:Principles of Nuclear Magnetic Resonance in One and Two Dimensions, Oxford science publications, 1990.

2) Mansfield, P., Mausley, A.A., Morris, P.G., Pykett, I.L.:J Magn Reson 33:261, 1979.

3) Abe, Z., Tanaka, K.:US Patent 3, 932805, filed 9, August 1973.

4) Bottomley, P. A.:Localized NMR spectroscopy by the sensitive point method. J Magn Reson 50:335-338, 1982.

5) Aue, WP., Muller, S., Cross, TA., Seelig, J.:Volume-Selective Excitation-A Novel-Approach to Topical NMR. J Magn Reson 56 (2):350-354, 1984.

6) Bottomley, P.A. US4733185:Methods for localization in NMR spectroscopy, 1988.
pubmed

7) Bottomley, P.A., Foster, T.B., Darrow, R.D.:Depth-resolved surface coil spectroscopy (DRESS) for in vivo 1H, 31P, and 13C NMR. J Mag. Reson 59:338, 1984.

8) Ordidge, R.J., Connelly, A., Lohman, J.A.B.:Image-selected in vivo spectroscopy (ISIS), a new technique for spatially selective NMR spectroscopy. J Magn Reson 66:283, 1986.

9) Howe, FA., Canese, R., Podo, F., Vikhoff, B., Slotboom, J.,Griffiths, JR., Henriksen, O., Bovee, W.M.:Quality assessment in in vivo NMR spectroscopy:V. Multicentre evaluation of prototype test objects and protocols for performance assessment in small bore MRS equipment. Magn Reson Imaging 13 (1):159-167, 1995.
pubmed

11) Ljungberg, M., Starck, G., Vikhoff-Baaz, B., Alpsten, M.,Ekholm, S., Forssell-Aronsson, E.:The magnitude of signal errors introduced by ISIS in quantitative 31P MRS. MAGMA 14 (1):30-8, 2002.
pubmed

12) Frahm, J., Merboldt, K.D., Hanicke, W.:Localized proton spectroscopy using stimulated echoes. J Magn Reson 72:502-8, 1987.

13) Moonen, C.T., van Zijl, P.C.M.:Highly effective water suppression for in vivo proton NMR spectroscopy (DRYSTEAM) . J Magn Reson 88:28-41, 1990.

14) Bottomley, P.A.:Spatial localization in NMR-spectroscopyin vivo . Ann NY Acad Sci 508:333-48, 1987.

P.89 掲載の参考文献

1) El-Sharkawy, A-M., Schar, M., Ouwerkerk, R., Weiss, R.G., Bottomley, P.A.:Quantitative cardiac 31P spectroscopy at 3 Tesla using adiabatic pulses. Magn Reson Med 61:785-795,2009.
pubmed

2) Verbruggen, K.T., Maurits, N.M., Meiners, L.C., Brouwer,O.F., van Spronsen, F.J., Sijens, P.E.:Quantitative multivoxel proton spectroscopy of the brain in developmental delay. J Magn Reson Imag 30:716-721, 2009.

3) Murakami, M., Seo, Y., Watari, H., et al.:31P-NMR studies on the isolated perfused mandibular gland of the rat. Jpn J Physiol 37:411-423, 1987.
pubmed

4) Shinar, H., Seo, Y., Ikoma, K., Kusaka, Y., Eliav, U., Navon,G.:Mapping the fiber orientation in articular cartilage at rest and under pressure studied by 1H double quantum filtered MRI. Magn Reson Med 48:322-330, 2002.

5) Weis, J., Johansson, L., Ortiz-Nieto, F., Ahlstrom, H.:Assessment of lipids in skeletal muscle by LCModel and AMARES. J Magn Reson Imag 30:1124-1129, 2009.

6) Bottomley, PA.:The trouble with spectroscopy papers. Radiology 181:344-350, 1991.
pubmed

巻頭カラー口絵

P.103 掲載の参考文献

1) Tamura, A., Graham, D.I., McCulloch, J., Teasdale, G.M.:Focal cerebral ischaemia in the rat; 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1:53-60, 1981.
pubmed

2) Belayev, L., Alonso, O.F., Busto, R., Zhao, W., Ginsberg, M.D.:Middle cerebral artery occlusion in the rat by intraluminal suture; Neurological and pathological evaluation of animproved model. Stroke 27:1616-1622, discussion 1623,1996.
pubmed

3) Gerriets, T., Li, F., Silva, M.D., Meng, X., Brevard, M.,Sotak, C.H., Fisher, M.:The macrosphere model; evaluation of a new stroke model for permanent middle cerebral arteryocclusion in rats. J Neurosci Methods 30:201-211, 2003.

4) Pulsinelli, W.A., Brierley, J.B.:A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10:267-272, 1979.
pubmed

5) Bito, Y., Ebisu, T., Hirata, S., Takegami, T., Yamamoto, Y.,Tanaka, C., Naruse, S.:Lactate discrimination incorporated into echo-planar spectroscopic imaging. Magn Reson Med 45:568-574, 2001.
pubmed

6) Takegami, T., Ebisu, T., Bito, Y., Hirata, S., Yamamoto, Y., Tanaka, C., Naruse, S., Mineura, K.:Mismatch between lactate and the apparent diffusion coefficient of water in progressive focal ischemia. NMR Biomed 14:5-11, 2001.
pubmed

7) Naruse, S., Horikawa, Y., Tanaka, C., Hirakawa, K., Nishikawa, H., Watari, H.:In vivo measurement of energy metabolism and the concomitant monitoring of electroen cephalogram in experimental cerebral ischemia. Brain Res 296:370-372, 1984.

8) Naruse, S., Horikawa, Y., Tanaka, C., Hirakawa, K., Nishikawa, H., Watari, H.:Measurements of in vivo energy metabolism in experimental cerebral ischaemia using 31P NMR for the evaluation of protective effects of perfluoro chemicals and glycerol. Neurol Res 6:169-175, 1984.

9) Sibson, N.R., Dhankhar, A., Mason, G.F., Behar, K.L., Rothman, D.L., Shulman, R.G.:In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate glutamine cycling. Proc Natl Acad Sci USA 18:2699-2704,1997.

10) Cerdan, S., Kunnecke, B., Seelig, J.:Cerebral metabolism of[1,2-13C2]acetate as detected by in vivo and in vitro 13C NMR. J Biol Chem 5:12916-12926, 1990.

11) Hassel, B., Sonnewald, U., Fonnum, F.:Glial-neuronalinteractions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose; An ex vivo 13C NMR spectroscopic study. J Neurochem J64:2773-2782, 1995.

12) Johansson, E., Mansson, S., Wirestam, R., Svensson, J., Petersson, J.S., Golman, K., Stahlberg, F.:Cerebral perfusion assessment by bolus tracking using hyperpolarized 31C. Magn Reson Med 51:464-472, 2004.

13) Ebisu, T., Rooney, W.D., Graham, S.H., Weiner, M.W.,Maudsley, A.A.:N-acetylaspartate as an in vivo marker of neuronal viability in kainate-induced status epilepticus:1H magnetic resonance spectroscopic imaging. J Cereb Blood Flow Metab 14:373-382, 1994.

14) Najm, I.M., Wang, Y., Hong, S.C., Luders, H.O., Ng, T.C., Comair, Y.G.:Temporal changes in proton MRS metabolites after kainic acid-induced seizures in rat brain. Epilepsia 38:87-94, 1997.

P.112 掲載の参考文献

1) Daly, P.F., Lyon, R.C., Faustino, P.J., et al.:Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 262:14875-14878, 1987.
pubmed

2) Bhakoo, K.K., Williams, S.R., Florian, C.L., et al.:Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 56:4630-4635, 1996.
pubmed

3) Griffin, J.L., Lehtimaki, K.K., Valonen, P.K., et al.:Assignment of 1H nuclear magnetic resonance visible polyun-saturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res 63 , 3195-3201, 2003.

4) Lehtimaki, K.K., Valonen, P.K., Griffin, J.L., et al.:Metabolitechanges in BT4C rat gliomas undergoing ganciclovirthymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo , ex vivo , and in vitro . J Biol Chem 278:45915-45923, 2003.
pubmed

5) Velonen, P.K., Griffin, J.L., Lehtimaki, K.K., et al.:High resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolitesupon gene therapy-induced programmed cell death in ratbrain glioma. NMR Biomed 18:252-259, 2005.

6) Griffiths, J.R., Stevens, A.N., Iles, R.A., et al.:31P NMR investigation of solid tumors in the living rat. Biosci Rep 1:319-325, 1981.
pubmed

7) Griffiths, J.R., Iles, R.A.:NMR studies of tumors. Biosci Rep 2:719-725, 1982.
pubmed

8) Evanochko, W.T., Ng, T.C., Lilly, M.B., et al.:In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci USA 80:334-338, 1983.

9) Koeze, T.H., Lantos, P.L., Iles, R.A., et al.:In vivo nuclear magnetic resonance spectroscopy of a transplanted brain tumour. Br J Cancer 49:357-361, 1984.
pubmed

10) Lilly, M.B., Ng, T.C., Evanochko, W.T., et al.:Loss of high-energy phosphate following hyperthermia demonstrated by in vivo 31P-nuclear magnetic resonance spectroscopy. Cancer Res 44:633-638, 1984.
pubmed

11) Naruse, S., Horikawa, Y., Tanaka, C., et al.:Observations of energy metabolism in neuroectodermal tumors using in vivo 31P-NMR. Magn Reson Imaging 3:117-123, 1985.
pubmed

12) Naruse, S., Hirakawa, K., Horikawa, Y., et al.:Measurement of in vivo 31P nuclear magnetic resonance spectra inneuroectodermal tumors for the evaluation of the effects of chemotherapy. Cancer Res 45:2429-2433, 1985.
pubmed

13) Naruse, S., Higuchi, T., Horikawa, Y., et al:Radiofrequency hyperthermia with successive monitoring of its effects on tumors using NMR spectroscopy. Proc Natl Acad Sci USA 83 ; 8342-8347, 1986.

14) Naruse, S., Horikawa, Y., Tanaka, C., et al:Evaluation of effects of photoradiation therapy on brain tumors within vivo P-31 MR spectroscopy. Radiology 160:827-830, 1986.

15) Koutcher, J.A., Motwani, M., Zakian, K.L., et al.:The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6:1498-1507, 2000.
pubmed

16) Rajan, S.S., Wehrle, J.P., Li, S.J., et al.:31P NMR spectroscopic study of bioenergetic changes in radiation-induced fibrosarcoma-1 after radiation therapy. NMR Biomed 2:165-171, 1989.
pubmed

17) Mahmood, U., Alfieri, A.A., Ballon, D., et al.:In vitro and in vivo 31P nuclear magnetic resonance measurements of metabolic changes post radiation. Cancer Res 55:1248-1254, 1995.
pubmed

18) Li, S.J., Wehrle, J.P., Rajan, S.S., et al.:Response of radiation-induced fibrosarcoma-1 in mice to cyclophosphamide monitored by in vivo 31P nuclear magnetic resonance spectroscopy. Cancer Res 48:4736-4742, 1988.
pubmed

19) Fichtner, K.P., Schirrmacher, V., Griesbach, A., etal.:Characterization of a murine lymphoma cell line by 31P NMR spectroscopy ; In vivo monitoring of the local anti-tumor effects of systemic immune cell transfer. Int J Cancer 66:484-495, 1996.

20) Stegman, L.D., Ben-Yoseph, O., Freyer, J.P., et al.:Invivo 31P MRS evaluation of ganciclovir toxicity in C6 gliomasstably expressing the herpes simplex thymidine kinase gene. NMR Biomed 9:364-368, 1996.

21) Ben-Yoseph, O., Lyons, J.C., Song, C.W., et al.:Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol 36:149-157, 1998.
pubmed

22) Fernandez, E.J., Maudsley, A.A., Higuchi, T., et al:1H spectroscopic imaging of rat brain at 7 tesla. Magn Reson Med 25:107-119, 1992.

23) Ross, B.D., Kim, B., Davidson, B.L.:Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpessimplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1:651-657, 1995.

24) Lindskog, M., Kogner, P., Ponthan, F., et al.:Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (1H MRS) . Br J Cancer 88:478-485, 2003.

25) Lindskog, M., Spenger, C., Jarvet, J., et al.:Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J Natl Cancer Inst 96:1457-1466, 2004.

26) Usenius, J.P., Vainio, P., Hernesniemi, J., et al.:Choline-containing compounds in human astrocytoma studied by 1H NMR spectroscopy in vivo and in vitro . J Neurochem 63:1538-1543, 1994.
pubmed

27) Tedeschi, G., Lundbom, N., Raman, R., et al.:Increased choline signal coinciding with malignant degeneration of cerebral gliomas ; A serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87:515-524, 1997.

28) Remy, C., von Kienlin, M., Lotito, S., et al.:In vivo 1H NMR spectroscopy of an intracerebral glioma in the rat. Magn Reson Med 9:395-401, 1989
pubmed

29) Zoula, S., Herigault, G., Ziegler, A., et al.:Correlation between the occurrence of 1H-MRS lipid signal, necrosisand lipid droplets during C6 rat glioma development. NMR Biomed 16:199-212, 2003.

30) Garcia-Martin, M.L., Herigault, G., Remy, C., et al.:Mapping extracellular pH in rat brain gliomas in vivo 1H magnetic resonance spectroscopic imaging:comparison with maps of metabolites. Cancer Res 61:6524-6531, 2001.
pubmed

31) Hakumaki, J. M., Poptani, H., Sandmair, A.-M., et al.:1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma:Implications for the in vivo detection of apoptosis. Nat . Med 5:1323-1327, 1999.
pubmed

32) de Graaf, R.A., Luo, Y., Terpstra, M., et al.:Spectral editing with adiabatic pulses. J Magn Reson B , 109:184-193, 1995.
pubmed

33) Hurd, R.E., Freeman, D.M.:Metabolite specific proton magnetic resonance imaging. Proc Natl Acad Sci USA 86:4402-4406, 1989.
pubmed

34) Freeman, D.M., Sotak, C.H., Muller, H.H., et al.:A double quantum coherence transfer proton NMR spectroscopy technique for monitoring steady-state tumor lactic acid levels in vivo . Magn Reson Med 14:321-329, 1990.
pubmed

35) Melkus, G., Morchel, P., Behr, V.C., et al.:Short-echo spectroscopic imaging combined with lactate editing in a single scan. NMR Biomed 21:1076-1086, 2008.

36) Thakur, S.B., Yaligar, J., Koutcher, J.A.:In vivo lactate signal enhancenent using binomial spectral-selective pulses in selective MQ coherence (SS-Sel MQC) spectroscopy. Magn Reson Med 62:591-598, 2009.

37) Rothman, D.L., Behar, K.L., Hetherington, H.P., et al.:1H-Observe/13C-decouple spectroscopic measurements oflactate and glutamate in the rat brain in vivo. Proc Natl Acad Sci USA 82:1633-1637, 1985.

38) Terpstra, M., Gruetter, R., High, W.B., et al.:Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 58:5083-5088, 1998.
pubmed

39) Xu, S., Yang, J., Shen, J.:In vivo 13C saturation transfer effect of the lactate dehydrogenase reaction. Magn Reson Med 57:258-264, 2007.

40) Deelchand, D.K., Shestov, A.A., Koski, D.M., et al.:Acetate transport and utilization in the rat brain. J Neurochem 109 (Supp 1):46-54, 2009.

41) Badar-Goffer, R. S., Bachelard, H. S., Morris, P. G.:Cerebral metabolism of acetate and glucose studied by 13C-n.m.r. spectroscopy ; A technique for investigating metabolic compartmentation in the brain. Biochem J 266:133-139, 1990.

42) Thelwall, P.E., Yemin, A.Y., Gillian, T.L., et al.:Noninvasive in vivo detection of glutathione metabolism in tumors. Cancer Res 65:10149-10153, 2005
pubmed

43) Keshari, K.R., Wilson, D.M., Chen, A.P., et al.:Hyperpolarized [2-13C]-fructose ; A hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc 131:17591-17596, 2009.
pubmed

44) Golman, K., in:t Zandt, R., Thaning, M.:Real-time metabolic imaging. Proc Natl Acad Sci USA 103:11270-11275, 2006.
pubmed

45) Golman, K., in:t Zandt, R., Lerche, M., et al.:Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66:10855-10860, 2006.

46) Chen, A.P., Albers, M.J., Cunningham, C.H., et al.:Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 58:1099-1106, 2007.
pubmed

47) Cunningham, C.H., Chen, A.P., Lustig, M., et al.:Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson 193:139-146, 2008.
pubmed

48) Larson, P.E., Bok, R., Kerr, A.B., et al.:Investigation of tumor hyperpolarized [1-13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med 63:582-591, 2010.
pubmed

49) Kettunen, M. I., Hu, D., Witney, T.H., et al.:Magnetization transfer measurements of exchange between hyperpolarized [1-13C]pyruvate and [1-13C]lactate in murine lymphoma. Magn Reson Med 63:872-880, 2010.
pubmed

50) Witney, T.H., Brindle, K.M.:Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopy. Biochem Soc Trans 38:1220-1224, 2010.
pubmed

51) Bachert, P.:Pharmacokinetics using fluorine NMR in vivo. Prog Nucl Magn Reson Spectrosc 33:1-56, 1998.

52) Gade, T.P.F., Buchanan, I.M., Motley, M.W., et al.:Imaging intratumoral convection ; Pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res 15:247-255, 2008.

53) Hamstra, D.A., Lee, K.C., Tychewicz, J.M., et al.:Theuse of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10:916-928, 2004.

54) Xing, L., Sun, X., Deng, X., et al.:Expression of bifunctional suicide gene CDUPRT increases radiosensitizationand by stander effect of 5-FC in prostate cancer cells. Radiother Oncol 92:345-352, 2009.

55) Schlemmer, H.P., Becker, M., Bachert P., et al.:Alterations of intratumoral pharmacokinetics of 5-Fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res 59:2363-2369, 1999.
pubmed

56) Cron, G.O., Beghein, N., Ansiaux, R., et al.:19F NMR in vivo spectroscopy reflects the effectiveness of perfusionenhancing vascular modifiers for improving gemicitabine chemotherapy. Magn Reson Med 59:19-27, 2008.

57) Spees, W.M., Grade, T.P.F., Yang, G., et al.:An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistence ; Proof of principle. Clin Cancer Res 11:1454-1461, 2005.

58) Porcari, P., Capuani, S., D:Amore, E., et al.:In vivo 19F MR imaging and spectroscopy for the BNCT optimization. Appl Radiat Isot 67:S365-368, 2009.
pubmed

59) Mason, R.P., Nunnally, R.L., Antich, P.P.:Tissue oxygenation; A novel determination using 19F surface coil NMR spectroscopy of sequestered perfluorocarbon emulsion. Magn Reson Med 18:71-79, 1991.
pubmed

60) Jordan, B.F., Cron, G.O., Gallez, B., et al.:Rapid monintoring of oxygenation by 19F magnetic resonance imaging ; Simultaneous comparison with fluorescence quenching. Magn Reson Med, 61:634-638, 2009.
pubmed

61) Magat, J., Jordan, B.F., Cron, G.O., et al.:Noninvasive mapping of spontaneous fluctuations in tumor oxygenationusing 19F MRI. Med Phys 37:5434-5441, 2010.
pubmed

62) Thulborn, K.R., Davis, D., Adams, H., et al.:Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn Reson Med 41:351-359, 1999.
pubmed

63) Babsky, A.M., Hekmatyar, K., Zhang, H., et al.:Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors. Neoplasia 7:658-666, 2005.

64) Winter, P.M., Poptani, H., Bansal, N.:Effects of chemotherapyby 1, 3-Bis (2-chloroethyl)-1-nitrosourea on single-quantum-and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of subcutaneously implanted 9L glioma. Cancer Res 61:2002-2007, 2001.

65) MacFall, J.R., Prescott, D.M., Charles, H.C., et al.:1H MRI phase thermometry in vivo in canine brain, muscle, andtumor tissue. Med Phys 23:1775-1782, 1996.

66) Hekmatyar, S.K., Poptani, H., Babsky, A., et al.:Non-invasive magnetic resonance thermometry using thulium-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetate (TmDOTA (-)) . Int J Hyperthermia 18:165-179, 2002.
pubmed

P.120 掲載の参考文献

1) Bessman, S.P., Carpenter, C.L.:The creatine-creatine phosphate energy shuttle. Ann Rev Biochem 54:831-862,1985.
pubmed

2) Yoshizaki, K.:31P-NMR study on intracellular energy transport in muscle. Muscle Energetics, 177-184, Alan R. Liss, Inc., 1989.

3) Yoshizaki , K ., Watari , H., Radda , G.K.:Role of phosphocreatine in energy transport in skeletal muscle of bullfrog studied by 31P-NMR. Biochim Biophys Acta 1051:144-150, 1990.
pubmed

4) 吉崎和男, 早野尚志, 平川和文:エネルギー産生の分子機構.分子の目でみた骨格筋の疲労, 吉岡利忠監修, ナップ, 252-274, 2003.

5) Wallimann, T., Wyss, M., Brdiczka, D., et al.:Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands:the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 281:21-40, 1992.
pubmed

6) Meyer, R.A., Sweeney, H.L., Kushmerick, M.J.:A simple analysis of the "phosphocreatine shuttle". Am J Physiol 246:C365-C377, 1984.
pubmed

7) Johnson Jr, C.S.:Diffusion ordered nuclear magnetic resonance spectroscopy:principles and applications. Prog NMR Spectrosc 34:203-256, 1999.

8) Yoshizaki, K., Seo, Y., Nishikawa, H., et al.:Application of pulsed-gradient 31P NMR on frog muscle to measure the diffusion rates of phosphorus compounds in cells. Biophys J 38:209-211, 1982.
pubmed

9) Yoshizaki, K., Nishikawa, H., Watari, H.:Diffusivities of creatine phosphate and ATP in an aqueous solution studied by pulsed field gradient 31P-NMR. Jpn J Physiol 37:923-928,1987.

10) Mills, R.:Self-diffusion in normal and heavy water in the range 1-45°. J Phys Chem 77:685-688, 1973.

11) Barrow, G. M.:Physical Chemistry for the Life Sciences. McGraw-Hill Co., 355-366, 1974.

12) Seraydarian, K., Mommaerts, W.F.H.M., Wallner, A.:The amount and compartmentalization of adenosine diphosphate in muscle. Biochim Biophys Acta 65:443-460, 1962.

13) Saks, V.A., Belikova, Y.O., Kuznetsov, A.V.:In vivo regulations of mitochondrial respiration in cardiomyocytes:specific restrictions for intracellular diffusion of ADP. Biochim Biophys Acta 1074:302-311, 1991.
pubmed

14) 老田達雄, 井本秀志, 相馬正幸・他:Creatine kinase MM 分画の欠損. 臨床病理 36:1045-1050, 1988.
Medical*Online

15) Koretsky, A.P., Brosnan, M.J., Chen, L., et al.:NMR detection of creatine kinase expressed in liver of transgenic mice:Determination of free ADP levels. Proc Natl Acad Sci USA 87:3112-3116, 1990.
pubmed

16) 吉崎和男:31P-飽和移動NMR法による細胞内クレアチン・キナーゼ反応の速度論的研究の動向.生物物理 26:179-183,1986.

17) van Deursen, J., Heerschap, A., Oerlemans, F., et al.:Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell 74:621-631, 1993.
pubmed

18) Nicolay, K., van Dorsten, F.A., Reese, T., et al.:In situ measurements of creatine kinase flux by NMR. The lessons from bioengineered mice. Mol Cell Biochem 184:195-208,1998.
pubmed

19) in't Zandt, H.J.A., de Groof, A.J.C., Renema, W.K.J., etal.:Presence of (phospho) creatine in developing and adult skeletal muscle of mice without mitochondrial and cytosolic muscle creatine kinase isoforms. J Physiol 548:847-858,2003.
pubmed

20) van Deursen, J., Ruitenbeek, W., Heerschap, A., et al.:Creatine kinase (CK) in skeletal muscle energy metabolism:A study of mouse mutants with graded reduction in muscle CK expresson. Proc Natl Acad Sci 91:9091-9095, 1994.

21) Yamamichi, H., Kasakura, S., Yamamori, S., et al.:Creatine kinase gene mutation in a patient with muscle creatine kinase deficiency. Clin Chem 47:1967-1973, 2001.

P.128 掲載の参考文献

1) Satoh, S., Tanaka, A., Hatano, E., et al.:Energy metabolism and regeneration in transgenic mouse liver expressing creatine kinase after major hepatectomy. Gastroenterology 110:1166-1174, 1996.
pubmed

2) Malloy, CR., Cunningham, CC., Radda, GK.:The metabolic state of the rat liver in vivo measured by 31P-NMR spectroscopy. Biochim Biophys Acta 885:1-11, 1986.

3) Morikawa, S., Inubushi, T., Kito, K., et al.:Chemical assessment of phospholipid and phosphoenergetic metabolites inregenerating rat liver measured by in vivo and in virtro 31P-NMR. Biochim Biophys Acta 1197:251-257, 1992.

4) Nabeshima, M., Moriyasu, F., Nishikawa, K., et al.:Evaluation of protective effects of prostaglandin E1 on ischemic liver damage with in vivo 31P-MR spectroscopy. Magn Reson Med 34:457-461, 1995.
pubmed

5) Takahashi, K., Shigemori, S., Nosaka, S., et al.:Effects of halothane and isoflurane on phosphoenergetic state of the liver during hemorrhagic shock in rats:an in vivo 31P nuclear magnetic resonance spectroscopic study. Anesth Analg 85:347-52, 1997.

6) Morikawa, S., Inubushi, T., Kito, K., et al.:Long-term observation of in vivo 31P NMR spectra in carbon tetra chloride-intoxicated rabbit liver using implanted wireless surface coil. NMR Biomed 8:3-8, 1995.

7) Changani, K. K., Bell, J. D., Iles, R. A.:13C-Glycogen deposition during pregnancy in the rat following routine meal feeding. Biochim Biophys Acta 1380:198-208, 1998.
pubmed

8) Inubushi, T., Morikawa, S., Kito, K., et al.:1H-detected invivo 13C NMR spectroscopy and imaging at 2T magneticfield; Efficient monitoring of 13C-labeled metabolites in the rat brain derived from 1-13C-glucose. Biochem Biophys Res Commun 191:866-872, 1993.

9) Morikawa, S., Inubushi, T.:Fast 13C-glucose metabolite mapping in rat brain using 1H echo planar spectroscopictechnique at 2T. J Magn Reson Imaging 13:787-791, 2001.
pubmed

10) Katz, J., Wals, P., Lee, WN.:Isotopomer studies of gluconeogenesis and the Krebs cycle with 13C-labeled lactate. J Biol Chem 268:25509-21, 1993.
pubmed

11) Morikawa, S., Inubushi, T., Takahashi, K., et al.:Glucose and Energy Metabolism in Rat liver after ischemic damage assessed by 13C and 31P NMR spectroscopy. J Surg Res 63:393-399, 1996.
pubmed

12) Morikawa, S., Inubushi, T., Takahashi, K., et al.:Relationship between gluconeogenesis and phosphoenergetics inrat liver assessed by in vivo 13C and 31P NMR spectroscopy. NMR Biomed 10:18-24, 1997.

13) Morikawa, S., Inubushi, T., Takahashi, K., et al.:Gluconeogenesis and phosphoenergetics in rat liver during endotoxemia. J Surg Res 74:179-186, 1998.
pubmed

14) Hazle, J.D., Narayana, P.A., Dunsford, H.A.:Chronic carbon tetrachloride and phospholipase D hepatotoxicity in rat; In vivo 1H magnetic resonance, total lipid analysis, and histology. Magn Reson Med 15:211-228, 1990.
pubmed

15) Ling, M., Brauer, M.:Ethanol-induced fatty liver in the rat examined by in vivo 1H chemical shift selective magnetic resonance imaging and localized spectroscopic methods. Magn Reson Imaging 10:663-77, 1992.
pubmed

16) Daubioul, C., Rousseau, N., Demeure, R., et al.:Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. J Nutr 132:967-973, 2002.

17) Delgado, TC., Pinheiro, D., Caldeira, M., et al.:Sources of hepatic triglyceride accumulation during high-fat feeding inthe healthy rat. NMR Biomed. 22:310-317, 2009.

18) Otsuka, H., Harada, M., Koga, K., et al.:Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. Magn Reson Imaging 17:283-90, 1999.

19) Brix, G., Bellemann, ME., Haberkorn, U., et al.:Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging. Magn Reson Med 34:302-307, 1995.
pubmed

20) Kito, K., Arai, T., Mori, K., et al.:Hepatic blood flow and energy metabolism during hypotension induced by prostaglandin E1 and nicardipine in rabbits; An in vivo magnetic resonance spectroscopic study. Anesth Analg 77:606-612,1993.

21) Gputa, A., Chacko, VP., Weiss, R.:Abnormal energetics and ATP depletion in pressure-overload mouse hearts; In vivo high-energy phosphate concentration measures by noninvasive magnetic resonance. Am J Physiol Heart Circ Physiol 297:H59-H64, 2009.
pubmed

22) Takaoka, A., Nakae, I., Mitsunami, K., et al.:Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits;Effects of"remote preconditioning". J Am Coll Cardiol 33:556-564, 1999.
pubmed

23) Kitai, T., Tanaka, A., Terasaki, M., et al.:Energy metabolism of the heart and the liver in brain dead dogs asassessed by 31P NMR spectroscopy. J Surg Res 55:599-606, 1993.

P.138 掲載の参考文献

1) Yoshimura, K., Nezu, E.:Dynamic changes in the rate of amylase release induced by various secretagogues examined in isolated rat parotid cells by using column perifusion. Jpn J Physiol 41:443-457, 1991.

2) Yoshimura, K., Fujita-Yoshigaki, J., Murakami, M., etal.:Cyclic AMP has distinct effects from Ca2+ in evoking proming and fusion/exocytosis in parotid amylase secretion. Pflugers Arch 444:586-596, 2002.

3) Foxall,D.L., Cohen,J.S.:NMR studies of perfused cells. J Magn Reson 52:346-349, 1983.

4) Boulanger, Y., Vinay,P., Phan-Viet, M.T., et al.:An improved perfusion system for NMR study of living cells. Magn Reson Med 2:495-500, 1985.

5) Oren-Shamir M., Avron, M., Degani, H.:In vivo NMR studies of the alga Dunaliella salina embedded in beads. FEBS lett 233:124-128, 1988.

6) 瀬尾芳輝, 村上政隆, 亘弘:代謝研究とその周辺の技術 1) NMRを用いて (その1)-H, P. 代謝 23, 83-90, 1986.

7) 塚本賢治, 村上政隆, 瀬尾芳輝・他:ラット低温保存肝の生理機能, 移植 22, 194-199, 1987.
Medical*Online

8) Takami, H., Seo, Y., Murakami, M., et al.:NMR-invisible ATP in rat heart and its change in ischemia. J Biochem 104:35-39, 1988.
pubmed

9) Hollis, D.P., Nunnally, R.L., Taylor, G.J., et al.:Phosphorus nuclear magnetic resonance studies of heart physiology. J Magn Reson 29:319-330, 1978.

10) Takano, T., Nakata, K., Kawakami, T., et al.:Validation of a toxicity testing model by evaluating oxygen supply andenergy state in the isolated perfused rat kidney. J Pharmacol Method 25:195-204, 1991.

11) Ratcliff, P.J., Endre, Z.H., Scheinman, S.J., et al.:31P-nuclear magnetic resonance study of steady-state adenosine 5'-triphosphate levels during graded hypoxiain the isolated perfused rat kidney. Clin Sci 74:437-448,1988.

12) 松本武久, 菅野富夫, 瀬尾芳輝・他:31P-NMR測定のための新しい膵灌流方法. 日磁医誌, 7, 223-232, 1988.

13) 市川修, 池田明聡, 鈴木賢-:灌流実験用電磁弁コントロールシステムの制作. 生理研技報告 3, 40-45, 1988.

14) 日本生理学会編:新・生理学実習書南江堂, 1991.

15) Murakami, M., Miyamoto, S., Imai, Y.:Oxygen consumptionfor K+ uptake during post-stimulatory activation of Na+,K+-ATPase in perfused rat mandibular gland. J Physiol 426:127-143, 1990.

16) 市川修, 大河原浩, 池田明聡・他:周辺実験技術と水電解質輸送研究のための多核種NMR法. 磁気共鳴スペクトル-臨床応用マニュアル, 第19章成瀬昭二編, 医学書院, 201-219,1994.

17) Murakami, M., Hashimoto, S., Wei, M., et al.:Morphophysiological approach to the paracellular route for salivary secretion by isolated perfused submandibular gland. J Med Invest , 50 suppl.:322-324, 2009.

18) Murakami, M., Mori, H., Nakahari, T., et al.:Method and application of weight differentiating flow meter. Jpn J Physiol 30:791-794, 1980.

19) Murakami, M., Seo, Y., Nakahari, T., et al.:Effects of Na+ depletion on fluid secretion and levels of phosphorus compounds as measured by 31P-NMR in perfused canine mandibular gland. Jpn J Physiol 34:587-597, 1984.
pubmed

20) プラスチック加工技術便覧編集委員会編:プラスチック加工技術便覧. 日刊工業新聞社, 1043-1047, 1969.

21) 特集エンジニアリングプラスチックの素顔. 工業材料 37 (4月号), 1989.

P.157 掲載の参考文献

1) Chuang, K. H., Koretsky, A.:Improved neuronal tract tracing using manganese enhanced magnetic resonance imaging with fast T (1) mapping. Magn Reson Med 55:604-611, 2006.

2) Le Bihan, D., et al.:Separation of diffusion and perfusionin intravoxel incoherent motion MR imaging. Radiology 168:497-505, 1988.

3) Moseley, M. E., et al.:Early detection of regional cerebral ischemia in cats ; Comparison of diffusion-and T2-weighted MRI and spectroscopy. Magn Reson Med 14:330-346,1990.
pubmed

4) Chenevert, T. L., McKeever, P. E., Ross, B. D.:Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3:1457-1466, 1997.
pubmed

5) Williams, D. S., Detre, J. A., Leigh, J. S., Koretsky, A.P.:Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA 89:212-216, 1992.
pubmed

6) Detre, J. A., Leigh, J. S., Williams, D. S., Koretsky, A. P.:Perfusion imaging. Magn Reson Med 23:37-45, 1992.
pubmed

7) Zhang, W., Williams, D. S., Koretsky, A. P.:Measurement of rat brain perfusion by NMR using spin labeling of arterial water ; In vivo determination of the degree of spin labeling. Magn Reson Med 29:416-421, 1993.
pubmed

8) Detre, J. A., et al.:Tissue specific perfusion imaging using arterial spin labeling. NMR Biomed 7:75-82, 1994.

9) Kim, S. G.:Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique ; Application to functional mapping. Magn Reson Med 34:293-301, 1995.
pubmed

10) Edelman, R. R., et al.:Qualitative mapping of cerebral blood flow and functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. Radiology 192:513-520, 1994.
pubmed

11) Wong, E. C., Buxton, R. B., Frank, L. R.:Quantitative imaging of perfusion using a single subtraction (QUIPSS and QUIPSS II) . Magn Reson Med 39:702-708, 1998.
pubmed

12) Louie, A. Y., et al.:In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18:321-325, 2000.
pubmed

13) Li, W. H., Parigi, G., Fragai, M., Luchinat, C., Meade, T.J.:Mechanistic studies of a calcium-dependent MRI contrastagent. Inorg Chem 41:4018-4024, 2002.

14) Lowe, M. P., et al.:pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J Am Chem Soc 123:7601-7609, 2001.
pubmed

15) Lin, Y. J., Koretsky, A. P.:Manganese ion enhances T1-weighted MRI during brain activation ; An approach to direct imaging of brain function. Magn Reson Med 38:378-388, 1997.
pubmed

16) Aoki, I., Naruse, S., Tanaka, C.:Manganese-enhanced magnetic resonance imaging (MEMRI) of brain activity and applications to early detection of brain ischemia. NMR Biomed 17:569-580, 2004.

17) Lu, H., et al.:Cocaine-induced brain activation detected by dynamic manganese-enhanced magnetic resonance imaging (MEMRI) . Proc Natl Acad Sci USA 104:2489-2494, 2007.
pubmed

18) Watanabe, T., Michaelis, T., Frahm, J.:Mapping of retinal projections in the living rat using high-resolution 3D gradient-echo MRI with Mn2+-induced contrast. Magn Reson Med 46:424-429, 2001.
pubmed

19) Aoki, I., Wu, Y. J., Silva, A. C., Lynch, R. M., Koretsky, A.P.:In vivo detection of neuroarchitecture in the rodent brain using manganese-enhanced MRI. Neuroimage 22:1046-1059, 2004.
pubmed

20) Pautler, R. G., Silva, A. C., Koretsky, A. P.:In vivoneuronal tract tracing using manganese-enhanced magnetic resonance imaging. Magn Reson Med 40:740-748, 1998.
pubmed

21) Yu, X., Wadghiri, Y. Z., Sanes, D. H., Turnbull, D. H.:In vivo auditory brain mapping in mice with Mn-enhanced MRI. Nat Neurosci 8:961-968, 2005.
pubmed

22) Bearer, E. L., et al.:Role of neuronal activity and kinesin on tract tracing by manganese-enhanced MRI (MEMRI). Neuroimage 37:Suppl 1, S37-46, 2007.

23) Van der Linden, A., et al.:In vivo manganese-enhanced magnetic resonance imaging reveals connections and functional properties of the songbird vocal control system. Neuroscience 112:467-474, 2002.
pubmed

24) Smith, K. D., Kallhoff, V., Zheng, H., Pautler, R. G.:Invivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 35:1401-1408, 2007.

25) Hoehn, M., et al.:Monitoring of implanted stem cellmigration in vivo ; A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA 99:16267-16272 (2002).

27) Reimer, P., Weissleder, R., Lee, A. S., Wittenberg, J., Brady, T. J.:Receptor imaging:application to MR imaging of liver cancer. Radiology 177:729-734, 1990.
pubmed

28) Weissleder, R., Lee, A. S., Khaw, B. A., Shen, T., Brady,T. J.:Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct ; MR antibody imaging. Radiology 182:381-385, 1992.
pubmed

29) Maeda, H., Matsumura, Y.:Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6:193-210, 1989.
pubmed

30) Ward, K. M., Aletras, A. H., Balaban, R. S.:A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST) . J Magn Reson 143:79-87, 2000.
pubmed

31) Zhang, S., Merritt, M., Woessner, D. E., Lenkinski, R. E.,Sherry, A. D.:PARACEST agents ; Modulating MRI contrastvia water proton exchange. Acc Chem Res 36:783-790,2003.
pubmed

32) Weissleder, R., et al.:In vivo magnetic resonance imaging of transgene expression. Nat Med 6:351-355, 2000.
pubmed

33) Cohen, B., et al.:MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med13:498-503, 2007.

34) Aung, W., et al.:Visualization of in vivo electroporation-mediated transgene expression in experimental tumors byoptical and magnetic resonance imaging. Gene Ther 16:830-839, 2009.

35) Cattel, L., Ceruti, M., Dosio, F.:From conventional to stealth liposomes ; A new Frontier in cancer chemotherapy. J Chemother 16 Suppl 4:94-97, 2004.

36) Gradishar, W. J.:Albumin-bound paclitaxel:a next-generation taxane. Expert Opin Pharmacother 7:1041-1053, 2006.
pubmed

37) Ponce, A. M., et al.:Magnetic resonance imaging of temperature-sensitive liposome release:drug dose painting and antitumor effects. J Natl Cancer Inst 99:53-63, 2007.
pubmed

目次

P.164 掲載の参考文献

1) Burt, C.T., Koutcher, J., Roberts, J.T., et al.:Magnetic resonance spectroscopy of the musculoskeletal system. Radiolo Clin North Am 24:321-331, 1986.

2) Cohen, J.S.:Phospholipid and energy metabolism of cancer cells monitored by 31P magnetic resonance spectroscopy;Possible clinical significance. Mayo Clin Proc 63:1199-1207, 1988.
pubmed

3) Shinkwin, M.A. Lenkinski, R.E., Daly, J.M., et al.:Integrated magnetic resonance imaging and phosphorus spectroscopyof soft tissue tumors. Cancer 67:1849-1858, 1991.

4) Happenstall, R.B., Sapega, A.A., Izant, T., et al.:Compartment syndrome:a quantitative study of high-energy phosphorus compounds using 31P-magnetic resonance spectroscopy. J Trauma 29:1113-1118, 1989.

5) Wolfe, C.L., Moseley, M.E., Wikstrom, M.G., et al.:Assessment of myocardial salvage after ischemia and reperfusion using magnetic resonance imaging and spectroscopy. Circulation 80:969-982, 1989.
pubmed

6) Hafner, H.P., Radu, E., Seelig, J.:Two-volume acquisition in image-guided proton spectroscopy. Magn Reson Med 15:135-141, 1990.
pubmed

7) Geppert, C., Dreher, W., Leibfritz, D.:PRESS-based proton single-voxel spectroscopy and spectroscopic imaging with very short echo times using asymmetric RF pulses. MAGMA 16:144-148, 2003.
pubmed

8) Gill, S.S., Small, R.K., Thomas, D.G., et al.:Brain metabolitesas 1H NMR markers of neuronal and glial disorders. NMR Biomed 2:196-200, 1989.

9) Demaerel, P., Johannik, K., van Hacke, P., et al.:Localized 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors. J Comput Assist Tomogr 15:67-76,1991.

10) Harada, M., Tanouchi, M., Nishitani, H., et al.:Non-invasice characterization of brain tumor by in-vivo proton magnetic resonance spectroscopy. Jpn J Cancer Res 86:329-332, 1995.

11) Davie, C.A., Hawkins C.P., Barker, G.J. et al.:Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117:49-58, 1994.
pubmed

12) Paviakis, S.G., Kinsley, P.B., Kaplan, G.P., et al.:Magnetic resonance spectroscopy;Use in monitoring MELAS treatment. Arch Neurol 55:849-852, 1998.

13) Huang, W., Alexander, G.E., Daly, E.M., et al.:High brain myoinositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome:a 1H MRS study. Am J Psyhiatry 156:1879-1886, 1999.

14) Provencher, S.W.:Estimation of metabolite concentrations from localized in vivo proton NM Rspectra. Magn Resona Med 30:672-679, 1993.

15) Harada, M., Miyoshi, H., Uno, M., et al.:Neuronal impairment of adult moyamoya disease detected by quantified proton MRS and comparison with cerebral perfusion by SPECT with Tc-99m HM-PAO;A trial of clinical quantification of metabolites. J Magn Reson Imaging 10:124-128, 1999.

16) Petroff, O.A., Spencer, D.D., Alger, J.R., et al.:High-fieldproton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 39:1197-1202, 1989.
pubmed

17) Katz, S., Rosen, M., MR imaging and MR spectroscopyin prostate cancer management. Radiol Clin North Am 44:723-734, 2006.

18) Roebuch, J.R., Cecil, K.M., Schnall, M.D., et al.:Humanbreast lesions:characterization with proton MR spectroscopy. Radiology 209:269-275, 1998.

19) Meisamy, S., Bolan, P.J., Baker, E.H., et al.:Neoadjuvant response with in vivo 1H MR spectroscopy-a pilot study at4T. Radiology 233, 424-431, 2004.

20) Al-Okaili, R.N., Krejza, J., Woo J.H., et al. Intraaxial brain masses;MR imaging-based diagnostic strategy-initial experience. Radiology 243:539-550, 2007.
pubmed

21) Day, S.E., Kettunen, M.I., Gallagher, F.A., et al.:Detecting tumor response to treatment using hyperpolarized 13C magneticresonance imaging and spectroscopy. Nature Med 13:1382-1387. 2007.

P.170 掲載の参考文献

1) Webb, P.G., Sailasuta, N., Kohler, S., et al.:Automated single-voxel proton MRS; Technical development and multisite verification. Magn Reson Med 31:365-373, 1994.
pubmed

2) Kreis R, Ernst T, Ross B.D:Development of the human brain ; In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 30:424-437,1993.
pubmed

3) Chang, L., Ernst, T., Osborn, D., Seltzer, W., Leonido-Yee,M., Poland, RE.:Proton spectroscopy in myotonic dystrophy; Correlations with CTG repeats. Arch Neurol 55:305-311, 1998.
pubmed

4) Louis, M.Teresi:A Practicing Radiologist Guide to MR Spectroscopy of the Brain. 2007 Xlibris Corporation

5) Tallan, H. H., Moore, S., Stein, W. H.:N-Acetyl-L-aspartic acid ; in brain. J Biol Chem 224:41-45,1956.

6) Birken, D. L., Oldendorf, W. H.:N-Acetyl-L-aspartic acid ; Aliterature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 13:23-31, 1989.

7) Pouwels, P.J., Frahm J.:Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 39:53-60, 1998.
pubmed

8) Zimmerman, M.E., Pan, J.W., Hetherington,. H.P., Lipton, M.L., Baigi, K., Lipton, R.B.:Hippocampal correlates of pain in healthy elderly adults ; A pilot study. Neurology 10;73 (19):1567-1570, 2009.

9) Kupers, R., Danielsen, E.R., Kehlet, H., Christensen, R., Thomsen, C.:Painful tonic heat stimulation induces GABA accumulation in the prefrontal cortex in man. Pain 142 (1-2):89-93, 2009.

10) Bottomley, P.A., Hart, H.R. Jr., Edelstein, W.A., Schenck, JF.,Smith,. LS., Leue, WM., Mueller. O.M., Redington, RW.:Anatomyand metabolism of the normal human brain studied by magnetic resonance at 1.5 tesla. Radiology 150:441-446, 1984.

11) Ordidge, R.J., Bowley, R.M., McHale, G.:A general approach to selection of multiple cubic volume elements using the ISIS technique. Magn Reson Med 8 (3):323-331, 1988.
pubmed

12) Kurhanewicz, J., Bok, R Nelson, S.J., Vigneron, D.B.:Current and potential applications of clinical 13C MR spectroscopy. J Nucl Med 49 (3):341-344, 2008.
pubmed

P.176 掲載の参考文献

1) Devos, A., Lukas, L., Suykens, J.A., et al.:Classification of brain tumours using short echo time 1H MR spectra. J Magn Reson 170:164-175, 2004.
pubmed

2) Meyerand, M.E., Pipas, J.M., Mamourian, A., Tosteson, T.D., Dunn, J.F.:Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 20:117-123, 1999.
pubmed

3) Ishimaru, H., Morikawa, M., Iwanaga, S., Kaminogo, M., Ochi, M., Hayashi, K.:Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol 11:1784-1791, 2001.
pubmed

4) Saraf-Lavi, E., Bowen, B.C., Pattany, P.M., Sklar, E.M., Murdoch, J.B., Petito, C.K.:Proton MR spectroscopy of gliomatosis cerebri; Case report of elevated myoinositol with normal choline levels. AJNR Am J Neuroradiol 24:946-951, 2003.
pubmed

5) Majos, C., Alonso, J., Aguilera, C., et al.:Proton magnetic resonance spectroscopy ((1) H MRS) of human brain tumours; Assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 13:582-591, 2003.
pubmed

6) Hazany, S., Hesselink, J.R., Healy, J.F., Imbesi, S.G.:Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 49:121-127. 2007.
pubmed

7) Majos, C., Alonso, J., Aguilera, C., et al.:Utility of proton MR spectroscopy in the diagnosis of radiologically atypicalintracranial meningiomas. Neuroradiology 45:129-136,2003.
pubmed

8) Opstad, K.S., Murphy, M.M., Wilkins, P.R., Bell, B.A., Griffiths, J.R., Howe, F.A.:Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 20:187-192, 2004.
pubmed

9) Law, M., Cha, S., Knopp, E.A., Johnson, G., Arnett, J., Litt, A.W.:High-grade gliomas and solitary metastases; Differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222:715-721, 2002.
pubmed

10) Opstad, K.S., Griffiths, J.R., Bell, B.A., Howe, F.A.:Apparent T (2) relaxation times of lipid and macromolecules; A study of high-grade tumor spectra. J Magn Reson Imaging 27:178-184, 2008.
pubmed

11) Candiota, A.P., Majos, C., Bassols, A., et al.:Assignment of the 2.03 ppm resonance in in vivo 1H MRS of human brain tumour cystic fluid; Contribution of macromolecules. MAGMA 17:36-46, 2004.
pubmed

12) Andre, E., Xu, M., Yang, D., et al.:MR spectroscopy in sinus mucocele; N-acetyl mimics of brain N-acetylaspartate. AJNR Am J Neuroradiol 27:2210-2213, 2006.

13) Tomoi, M., Kimura, H., Yoshida, M., et al.:Alterations of lactate (+lipid) concentration in brain tumors with in vivo hydrogen magnetic resonance spectroscopy during radiotherapy. Invest Radiol 32:288-296, 1997.
pubmed

14) Huang, M.Q., Nelson, D.S., Pickup, S., et al.:In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad Radiol 14:1531-1539, 2007.
pubmed

15) Chernov, M.F., Hayashi, M., Izawa, M., et al.:Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery; 1H-MRS study. Brain Tumor Pathol 21:63-67, 2004.
pubmed

16) Kamada, K., Houkin, K., Abe, H., Sawamura, Y., Kashiwaba, T.:Differentiation of cerebral radiation necrosisfrom tumor recurrence by proton magnetic resonance spectroscopy. Neurol Med Chir 37:250-256, 1997.

17) Moller-Hartmann, W., Herminghaus, S., Krings, T., etal.:Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44:371-381, 2002.
pubmed

P.182 掲載の参考文献

1) Haimes,A.B., Zimmerman,R.D., Morgello,S., et al.:MR imaging of brain abscesses. AJNR 10:279-291, 1989.

2) Kjos,B.O., Brant-Zawadzki,M., Kucharczyk,W., et al.:Cystic intracranial lesions;Magnetic resonance imaging. Radiology 155:363-369, 1985.
pubmed

3) Ebisu,T., Tanaka,C., Umeda,M., et al.:Discrimination of brain abscess from necrotic or cystic tumors by diffusion weighted echo planar imaging. Magn Reson Imaging 14:1113-1116, 1996.
pubmed

4) Reddy,J.S., Mishra,A.M., Behari,S., et al:The role of diffusion-weighted imaging in the differential diagnosis ofintracranial cystic mass lesions;A report of 147 lesions. Surg Neurol 66:246-50, 2006.

5) Mishra,A.M., Gupta,R.K., Saksena,S., et al.:Biological correlates of diffusivity in brain abscess. Magn Reson Med 54:878-85, 2005.
pubmed

6) Mueller-Mang,C., Castillo,M., Mang,T.G., et al.:Fungal versus bacterial brain abscesses;Is diffusion-weighted MR imaging a useful tool in the differential diagnosis? Neuroradiology 49:651-657, 2007.
pubmed

7) Fertikh,D., Krejza,J., Cunqueiro,A., et al.:Discrimination of capsular stage brain abscesses from necrotic or cystic neoplasms using diffusion-weighted magnetic resonance imaging. J Neurosurg 106:76-81, 2007.
pubmed

8) Demaerel,P., Van Hecke,P., Van Oostende,S., et al.:Bacterial metabolism shown by magnetic resonance spectroscopy. Lancet 344:1234, 1994.
pubmed

9) Grand,S., Passaro,G., Ziegler,A., et al.:Necrotic tumor versus brain abscess;Importance of amino acids detected at 1H MR spectroscopy-initial results. Radiology 213:785-793, 1999.
pubmed

10) Kim,S.H., Chang,K-H., Song,I.C., et al.:Brain abscess and brain tumor;Discrimination with in vivo H-1 MR spectroscopy. Radiology 204:239-245, 1997.
pubmed

11) Harada,M., Tanouchi,M., Miyoshi,H., et al.:Brain abscess observed by localized proton magnetic resonance spectroscopy. Magn Reson Imaging 12:1269-1274, 1994.
pubmed

12) Poptani,H., Gupta,R.K., Jain,V.K., et al.:Cystic intracranial mass lesions:possible role of in vivo MR spectroscopy in its differential diagnosis. Magn Reson Imaging 11:443-449,1993.

13) Remy,C., Grand,S., Lai,E.S., et al.:1H MRS of human brain abscesses in vivo and in vitro . Magn Reson Med 34:508-514, 1995.
pubmed

14) Ott,D., Hennig,J., Ernst,T., et al.:Human brain tumors:Assessment with in vivo proton MR spectroscopy. Radiology 186:745-752, 1993.
pubmed

15) Gorbach,S.L., Mayhew,J.W., Bartlett,J.G., et al.:Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical specimens. J Clin Invest 57:478-484, 1976.
pubmed

16) Deacon,A.G., Duerden,B.I., Holbrook,W.P.:Gas-liquid chromatographic analysis of metabolic products in the identification of bacteroidaceae if clinical interest. J Med Microbiol 11:81-99, 1977.

17) Kugel,H., Heindel,W., Ernestus,R.I., et al.:Human brain tumors;Spectral patterns detected with localized H-1 MR spectroscopy. Radiology 183:701-709, 1992.
pubmed

18) Mendz,G.L., McCall,M.N., Kuchel,P.W.:Identification of methyl resonences in the 1H NMR spectrum of incubated blood cell lysates. J Biol Chem 264:2100-2107, 1989.
pubmed

19) Himmeireich,U., Accurso,R., Malik,R., et al.:Identification of staphylococcus aureus brain abscesses;Rat and human studies with 1H MR spectroscopy. Radiology 236:261-270, 2005.

20) Menon,D.K., Sargentoni,J., Peden,C.J., et al.:Proton MR spectroscopy in herpes simplex encephalitis; Assessment of neuronal loss. J Comput Assist Tomogr 14:449-452, 1990.

21) Samann,P.G., Schlegel,J., Muller,G., et al.:Serial proton MR spectroscopy and diffusion imaging findings in HIV-related herpes simplex encephalitis. Am J Neuroradiol 24:2015-2019, 2003.
pubmed

22) Takanashi,J., Sugita,K., Ishii,M., et al.:Longitudinal MR imaging and proton MR spectroscopy in herpes simplex encephalitis. J Neurol Sci 149:99-102, 1997.
pubmed

23) Jayasundar,R., Singh,V.P., Raghunathan,P., et al.:Inflammatory gramulomas:Evaluation with proton MRS. NMR Biomed 12:139-144, 1999.

24) Meyerhoff,D.J., MacKay,S., Bachman,L., et al:Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals;In vivo 1H magnetic resonance spectroscopic imaging. Neurology 43:509-515, 1993.

25) Meyerhoff,D.J., Bloomer,C., Cardenas,V., et al.:Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV patients. Neurology 52:995-1003,1999.
pubmed

26) Moller,H.E., Vermathen,P., Lentschig,M.G., et al.:Metabolic characterization of AIDS-dementia complex by spectroscopic imaging. J Magn Reson Imaging 9:10-18,1999.
pubmed

27) Aydin,K., Tatli,B., Ozkan,M., ey al.:Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS, Neurology 67:911-913. 2006.

28) Takashima,H., Eriguchi,M., Nakamura,T., et al.:Interferon therapy-responsive brain metabokic abnormalities in a case of adult-onset subacute sclerosing panencephalitis evaluated by 1H-MRS analysis. J Neurol Sci 207:59-83, 2003.

P.190 掲載の参考文献

1) Jones, TH., Morawetz, RB., Crowell, RM., et al.:Thresholdsof focal cerebral ischemia in awake monkeys. J Neurosurg 54:773-782,1982.

2) Astrup, J., Siesjo BK., Symon, L.:Thresholds in cerebralischemia-the ischemic penumbra. Stroke 12:723-725,1981.

3) Tallan, HH., Moore, S., Stein, WH.:N-Acetyl-L-aspartic acidin brain. J Biol Chem 219:257-264, 1956.

4) Munoz Maniega, S., Cvoro, V., et al.:Changes in NAA andlactate following ischemic stroke:a serial MR spectroscopicimaging study. Neurology 71:1993-1999, 2008.

5) Baslow, MH.:Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain, role inglial cell-specific signaling. J Neurochem 75:453-459,2000.

6) Bates, TE., Strangward, M., Keelan, J., et al.:Inhibition of N-acetylaspartate production:implications for H-MRS studies in vivo . Neuroreport 7:1397-1400, 1996.

7) Moffett, JR., Ross, B., Arun, P., et al.:N-Acetylaspartate inthe CNS:from neurodiagnostics to neurobiology. Prog Neurobiol81:89-131, 2007.

8) Choi, IY., Gruetter, R.:Dynamic or inert metabolism? Turnoverof N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat brain in vivo . J Neurochem 91:778-787,2004.

9) Benarroch, EE.:N-acetylaspartate and N-acetylaspartylglutamate:neurobiology and clinical significance. Neurology 70:1353-1357, 2008.

10) Bates, TE., Strangward, M., Keelan, J., et al.:Inhibition of N-acetylaspartate production:implications for 1H-MRS studies in vivo. Neuroreport 7:1397-1400, 1996.

11) Sager, TN., Fink-Jensen, A., Hansen, AJ.:Transient elevationof interstitial N-acetylaspartate in reversible global brainischemia. J Neurochem 68:675-682,1997.

12) Igarashi, H., Kwee, IL., Nakada, T., et al.:1H magneticresonance spectroscopic imaging of permanent focal cerebral ischemia in rat:longitudinal metabolic changes in ischemiccore and rim. Brain Res 907:208-221, 2001.

13) Cvoro, V., Wardlaw, JM., Marshall, I., et al.:Associations between diffusion and perfusion parameters, N-acetyl aspartate,and lactate in acute ischemic stroke. Stroke 40:767-772, 2009.
pubmed

14) Gideon, P., Henriksen, O., Sperling, B., et al.:Early timecourse of N-acetylaspartate, creatine and phosphocreatine,and compounds containing choline in the brain after acutestroke. A proton magnetic resonance spectroscopy study.Stroke 23:1566-1572, 1992.

15) Munoz Maniega, S., Cvoro, V., Armitage, PA., et al.:Choline and creatine are not reliable denominators for calculatingmetabolite ratios in acute ischemic stroke. Stroke 39:2467-2469, 2008.

16) Law, M.:MR spectroscopy of brain tumors. Top Magn Reson Imaging 15:291-313, 2004.17) Nicoli, F., Lefur, Y., Denis, B., et al.:Metabolic counterpartof decreased apparent diffusion coefficient during hyperacuteischemic stroke:a brain proton magnetic resonancespectroscopic imaging study. Stroke 34:e82-87, 2003.

18) Stengel, A., Neumann-Haefelin, T., Singer, OC., et al.:Multiple spin-echo spectroscopic imaging for rapid quantitativeassessment of N-acetylaspartate and lactate in acutestroke. Magn Reson Med 52:228-238, 2004.

19) Monsein, LH., Mathews, VP., Barker, PB., et al.:Irreversibleregional ischemia, Serial MR imaging and proton spectroscopyin a non-human primate model. Am J Neuroradiol 14:963-970, 1993.

20) Munoz Maniega, S., Cvoro, V., et al.:Changes in NAA and lactate following ischemic stroke, a serial MR spectroscopicimaging study. Neurology 71:1993-1999,2008.

21) Gideon, P., Henriksen, O., Sperling, B., et al.:Early timecourse of N-acetylaspartate, creatine and phosphocreatine,and compounds containing choline in the brain after acutestroke. A proton magnetic resonance spectroscopy study.Stroke 23:1566-1572, 1992.

22) Kagansky, N., Levy, S., Knobler, H.:The role of hyperglycemiain acute stroke. Arch Neurol. 58:1209-1212, 2001.

23) Henriksen, O., Gideon, P., Sperling, B., et al.:Cerebrallactate production and blood flow in acute stroke. J Magn Reson Imaging 2:511-517, 1992.
pubmed

24) Parsons, M.W., Barber, P.A., Desmond, P.M., et al.:Acute hyperglycemia adversely affects stroke outcome, a magneticresonance imaging and spectroscopy study. Ann Neurol 52:20-28, 2002.

25) Memezawa, H., Smith, M.L., Siesjo, B.K.:Penumbral tissues salvaged by reperfusion following middle cerebral arteryocclusion in rats. Stroke 23:552-559, 1992.

26) Garcia, J.H., Lassen, N.A., Weiller, C., et al.:Ischemic stroke and incomplete infarction. Stroke 27:761-765, 1996.
pubmed

27) Baron, J.C.:How healthy is the acutely reperfused ischemic penumbra? Cerebrovasc Dis 20 (Suppl 2):25-31,2005.

28) Rutgers, D.R., van Osch, M.J., Kappelle, L.J., et al.:Cerebral hemodynamics and metabolism in patients with symptomaticocclusion of the internal carotid artery. Stroke 34:648-652, 2003.
pubmed

29) Lythgoe, D., Simmons, A., Pereira, A., et al.:Magnetic resonance markers of ischaemia, their correlation with vasodilatoryreserve in patients with carotid artery stenosis and occlusion. J Neurol Neurosurg Psychiatry 71; 58-62, 2001.
pubmed

30) Rutgers, D.R., Klijn, C.J., Kappelle, L.J., et al.:Cerebral metabolic changes in patients with a symptomatic occlusionof the internal carotid artery, a longitudinal 1H magnetic resonancespectroscopy study. J Magn Reson Imaging 11:279-286, 2000.

31) Franke, C., Brinker, G., Pillekamp, F., et al.:Probability of Metabolic Tissue Recovery After Thrombolytic Treatment of Experimental Stroke, A Magnetic Resonance Spectroscopic Imaging Study in Rat Brain. J cereb blood flow metab 20:583-591, 2000.

P.197 掲載の参考文献

1) De Stefano, N., Matthews, P.M., Fu, L., et al.:A xonal damage correlates with disability in patients with relapsingremitting multiple sclerosis results of a longitudinal magnetic resonance spectroscopy. Brain 121:1469-1477, 1998.

2) Bakshi, R., Thompson, A.J., Rocca, M.A., et al.:MRI in multiples clerosis current status and future prospects. Lancet Neurol, 7:615-625, 2008.

3) Rovira, A., Leon, A.:MR in the diagnosis and monitoring of multiple sclerosis ; An overview. Eur J Radiol 67:409-414,2008.
pubmed

4) Mader, I., Rauer, S., Gall, P., et al.:1H MR spectroscopyof inflammation, infection and ischemia of the brain. Eur JRadiol 67:250-257, 2008.

5) Summers, M., Swanton, J., Fernando, K., et al.:Cognitiveimpairment in multiple sclerosis can be predicted by imagingearly in the disease. J Neurol Neurosurg Psychiatry 79:955-958, 2008.

6) Ciafoni, A., Niku, S., Imbesi, S.G.:Metabolite findings intumefactive demyelinating lesions utilizing short echo timeproton magnetic resonance spectroscopy. Am J Neuroradiol 28:272-277, 2007.
pubmed

7) Kappeler, P., Ropele, S., Enzinger, C., et al.:Discrimination of white matter lesions and multiple sclerosis plaques byshort echo quantitative 1H-magnetic resonance spectroscopy. J Neurol 252:1229-1234, 2005.

8) Khan, O., Shen, Y., Bao, F., et al.:Long-term study of brain 1H-MRS study in multiple sclerosis effect of glatirameracetate therapy on axonal metabolic function and feasibility of long term 1H-MRS monitoring in multiple sclerosis. J Neuro imaging 18:314-319, 2008.

9) De Stefano, N., Filippi, M, Miller, D., et al.:Guideline forusing proton MR spectroscopy in multicenter clinical MS studies. Neurology 69:1942-1952, 2007.
pubmed

10) Blamire, A.M., Cader, S., Lee, M., et al.:A xonal damagein the spinal cord of multiple sclerosis patients detected bymagnetic resonance spectroscopy. Magn Reson Med 58:880-885, 2007.

11) Grodd, W., Krageloh-Mann, I., Klose, U., et al.:Metabolic and destructive brain disorders in children; Findings withlocalized proton MR spectroscopy. Radiology 181:173-181,1991.
pubmed

12) Confort-Gouny, S., Vion-Dury, J., Chabroi, B., et al.:Localised proton magnetic resonance spectroscopy in X-linked adrenoleuiodystrophy. Neuroradiol 37:568-575, 1995.

13) Eichler, F.S., Barker, P.B., Cox, C., et al.:proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 58:901-907,2002.

14) Engelbrecht, V., Rassek, M., Gartner, J., et al.:The value of new MRI techniques in adrenoleukodystrophy. Pediatr Radiol 27:207-215, 1997.
pubmed

15) Pouwels, P.J., Kruse, B., Korenke, G.C., et al.:Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 29:254-264, 1998.
pubmed

16) 海蘭, 原田雅史, 西谷弘, 他:骨髄移植前後にプロトンMRSにより脳内代謝評価を行った副腎白質ジストロフィーの1例・臨床放射線 54:1269-1273, 2009.

17) Wilken, B., Dechent, P., Brockmann, K., et al.:Quantitative proton magnetic resonance spectroscopy and after hematopoietic stem cell transplantation. Neuropediatrics 34:237-246, 2003.
pubmed

18) Mathews, P.M., Andermann, F., Silver, K., et al.:proton MR spectroscopic characterization of differences in regionalbrain metabolic abnormalities in mitochondrial encephalopathies.Neurology 43:2484-2490, 1993.
pubmed

19) Castillo, M., Kwochk, L., Green, C.:MELAS syndrome:imaging and proton MR spectroscopic findings. Am J Neuroradiol 16:233-239, 1995.

20) Harada, M., Tanouchi, M., Arai, K., et al.:Therapeuticefficacy of a case of pyruvate dehydrogenase complex deficiency monitored by localized proton magnetic resonance spectroscopy. Magn Reson Imaging 14:129-133, 1996.

21) Lam W.W.M., Wang, Z.J., Zhao, H., et al.:1H MR spectroscopy of the basla ganglia in childhood; A semiquantitativeanalysis. Neuroradiology 40:315-323, 1998.

22) Lucetti, C., Del Dotto, P., Gambaccini, G., et al.:proton magnetic resonance spectroscopy of motor cortex and basalganglia in de novo Parkinson:s disease patients. Neurolo Sci 22:69-70, 2001.

23) Hu M.T., Taylor-Robinson, S.D., Chaudhun, K.R., et al.:Evidence for cortical dysfunction in clinically non-demented patients with Parkinson:s disease ; A proton MR spectroscopystudy. J Neurol Neurosug Psychiatry 67:20-26, 1999.

24) Lecetti, C., Del Dotto, P., Gambaccini, G., et al.:Influenceof dopaminergic treatment on motor cortex in Parkinson:sdisease ; A MRI/MRS study. Mov Disord 22:2170-2175,2007.

25) Llumiguano, C., et al.:1H-MRS experiences after bilateral DBS of the STN in Parkinson:s disease. Parkinsonism Relat Disord 14:229-232, 2008.
pubmed

26) Griffith, H.R., et al.:Reduced brain glutamate in patientswith Parkinson:s disease. NMR Biomed 21:381-387, 2008.

27) Bender, A., Auer, D.P., Meri, T., et al.:Creatine supplementation lowers brain glutamate levels in Huntington:s disease.J Nurol 252:36-41, 2005.

28) Reynolds, N.C. Jr., Prost, R.W., Mark, L.P.:Heterogeneityin 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Research 22:2052, 2056,2007.

29) Ruocco, H.H., Lopes-Cendes, I. Li, L.M., et al.:Evidence of thalamic dysfunction in Huntington's disease by proton magnetic resonance spectroscopy. Mov Disord 22:2052-2056,2007.
pubmed

30) Gomez-Anson, B., Alegret, M., Munoz, E., et al.:Decreased frontal choline and neuropsychological performance in preclinical Huntington's disease. Neurology 68:906-910, 2007.
pubmed

31) van Oostrom J.C., Sijens, P.E., Roos, R.A., et al.:1H magnetic resonance spectroscopy in preclinical Huntington:sdisease. Brain Res 1168:67-71, 2007.

32) Chan, S., Shungu, D.C., Douglas-Akinwande, A., et al.:Motor neuron diseases comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of thebrain. Radiology 212:763-769, 1999.

33) Sarchielli, P., Pelliccioli, G.P., Tarducci, R., et al.:Magnetic resonance imaging and 1H-magnetic resonance spectroscopyin amyotrophic lateral sclerosis. Neuroradiol 43:189-197, 2001.

34) Unrath, A. Ludolph, A.C., Kassubek, J., et al.:Brain metabolites in definite amyotrophic lateral sclerosis ; A longitudinalproton magnetic resonance spectroscopy study. J Neurol 254:1099-1106, 2007.
pubmed

35) Sarac, H., Zagar, M., Vranjes, D., et al.:Magnetic resonanceimaging and magnetic resonance spectroscopy in apatients with amyotrophic lateral sclerosis and frontotemporaldementia. Coll Antropol 32:205-210, 2008.

36) Niessen, H.G., Debska-Vielhaber, G., Sander, K., et al.:Metabolic progression markers of neurodegeneration in thetransgenic G93A-SOD1 mouse model of amyotrophic lateralsclerosis. Eur J Neurosci 25:1669-1677, 2007.

37) Watanabe, H., Fukatsu, H., Katsuno, M., et al.:Multiple regional 1H-MR spectroscopy in multiple system atrophy ;NAA/Cr reduction in pontine base as a valuable diagnosticmarker. J Neurol Neurosurg Psychiatry 75:103-109, 2004.

38) Boesch S.M., Wolf, C., Seppi, K., et al.:Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaing 25:564-569,2007.

39) Miyazaki, M., Kato, T., Hashimoto, T., et al.:MR of childhood-onset dentatorubral-pallidoluysian atrophy. Am J Neuroradiol 16:1834-1836, 1995.
pubmed

40) Miyazaki, M., Hashimoto, T., Yoneda, Y., et al.:protonmagnetic resonance spectroscopy on childhood-onset dentatorubral-pallidoluysian atrophy (DRPLA) . Brain Dev 18:142-146, 1996.

41) Kin, T., Hirano, M., Taoka, T., et al.:proton MR spectroscopyof adult-onset Dentatorubral-pallidoluysian atrophy.Magn Reson Med Sci 4:123-127, 2005.

P.206 掲載の参考文献

1) Danielsen, E.R., Ross, B.:The clinical significance ofmetabolites. In Danielsen E.R., Ross B. eds. Magnetic resonancespectroscopy diagnosis of neurological diseases.23-43, 1999.

2) Van der Knaap, M.S., Valk, J.:Magnetic resonance spectroscopy; Basic principles, and application in white matterdisease. Magnetic resonance of myelination and myelin disorders.3rd ed. 859-880, 2005.

3) Takanashi, J., Inoue, K., Tomita, M., et al.:Brain N acetyaspartateis elevated in Pelizaeus-Merzbacher disease. Neurology 58:237-241, 2002.

4) Takanashi, J., Kurihara, A., Tomita, M., et al.:Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency. Neurology 59:210-214, 2002.
pubmed

5) Takanashi, J., Sugita, K., Osaka, H., et al.:Proton MR spectroscopyin Pelizaeus-Merzbacher disease. Am J Neuroradiol AJNR 18:533-535, 1997.

6) Takanashi, J., Somazawa, F., Murayama, K., et al.:Metabolic changes in early childhood using LCModel with correctedwater scaling method. J Magn Reson Imaging 35:174-180, 2012.

7) Martin, E., Capone, A., Schneider, J., et al.:Absence of N-acetylaspartate in human brain;Impact on neurospectroscopy.Ann Neurol 49:518-521, 2001.

8) Sijens, P.E., Verbruggen, K.T., Meiners, L.C., et al.:H chemicalshift imaging of the brain in guanidine methyltransferasedeficiency, a creatine deficiency syndrome; Guanitinoacetate accumulation in the gray matter. Eur Radiol 15:1923-1926,2005.

9) Ensenauer, R., Thiel, T., Schwab, K.O., et al.:Guanidinoacetate methyltransferase deficiency, differences of creatine uptake in human brain and muscle. Mol Genet Metab 82:208-213, 2004.
pubmed

10) Leuzzi, V., Bianchi, M.C., Tosetti, M., et al.:Brain creatinedepletion;Guanidinoacetate methyltransferase deficiency (improving with creatine supplementation) . Neurology 55:1407-1409, 2000.
pubmed

11) Ganesan, V., Johnson, A., Connelly, A., et al.; Guanidinoacetatemethyltransferase deficiency;New clinical features.Pediatr Neurol 17:155-157, 1997.

12) Sijens, P.E., Verbruggen, K.T., Oudkerk, M., et al.:1H MRspectroscopy of the brain Cr transporter defect. Mol Genet Metab 86:421-422, 2005.

13) deGrauw, T.J., Cecil, K.M., Bryars, A.W., et al.:The clinical syndrome of creatine transporter deficiency. Mol Cell Biochem 244:45-48, 2003.

14) Mancini, G.M.S., Catsman-Berrevoets, C.E., de Coo,I.F.M., et al.:Two novel mutations in SLC6A8 cause creatinetransporter defect and distinctive X-linked mental retardationin two unrelated Dutch families. Am J Med Genet 132:288-295, 2005.

15) Battini, R., Leuzzi, V., Carducci, C., et al.:Creatine depletionin a new case with AGAT deficiency, clinical and geneticstudy in a large pedigree. Mol Genet Metab 77:326-331,2002.

16) Grodd, W., Krageloh-Mann, I., Petersen, D., et al.:In vivo assessment of N-acethylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy. Lancet 336 (8712):437-438, 1990.

17) Gripp, K.W., Zimmerman, R.A., Wang, Z.J., et al.:Imaging studies in a unique familial dysmyelinating disorder. Am J Neuroradiol 19:1368-1372, 1998.

18) Vorho, T.V., Komu, M., Sonninen, P., et al.:A new metabolite contributing to N-acethyl signal in 1H MRS of the brain in Salla disease. Neurology 52:1668-1672, 1999.

19) Mano, T., Ono, J., Kaminaga, T., et al.:Proton MR spectroscopyof Sjogren-Larsson syndrome. Clinical and MRI/MRS findings in FALDH-deficient patients. Am J Neuroradiol 20:1671-1673, 1999.

20) Van Domburg, P.H.M.F., Willemsen, M.A.A.P., Rotteveel,J.J., et al.:Sjogren-Larsson syndrome;Clinical and MRI/MRS findings in FALDH-deficient patients. Neurology 52:1345-1352, 1999.

21) Brockmann, K., Bjornstad, A., Dechent, P., et al.:Succunatein dystrophic white matter;A proton magnetic resonancespectroscopy finding characteristic for complex II deficiency.Ann Neurol 52:38-46, 2002.

22) Jan, W., Zimmerman, R.A., Wang, Z.J., et al.:MR diffusionand MR spectroscopy of maple syrup urine disease duringacute metabolic decompensation. Neuroradiology 45:393-399, 2003.

23) Otaduy, M.C.G., Leite, C.C., Lacerda, M.T.C., et al.:Proton MR spectroscopy and imaging of a galactosemic patientbefore and after dietary treatment. Am J Neuroradiol 27:204-207, 2006.

24) Huisman, T.A.G.M., Thiel, T., Steinmenn, B., et al.:Proton magnetic resonance spectroscopy of the brain of a neonatewith nonketotic hyperglycinemia;in vivo-in vitro (ex vivo) correlation. Eur Radiol 12:858-861, 2002.

25) Huck, J.H.J., Verhoeven, N.M., Struys, E.A., et al.:Ribose-5-phosphate isomerase deficiency;New inborn error in thepentose phosphate pathway associated with a slowly progressive leukoencephalopathy. Am J Hum Med 74:745-751,2004.

26) Wilken, B., Dechent, P., Hanefeld, F., et al.:Proton MRS of a child with Sandhoff disease reveals elevated brain hexosamine.Eur J Pediatr Neurol 12:56-60, 2008.

27) Leuzzi, V., Tosetti, M., Montanaro, D., et al.:The pathogenesisof the white matter abnormalities in phenylketonuria.A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J Inherit Metab Dis 30:209-216,2007.

28) Oner, A.Y., Cansu, A., Akpek, S., et al.:Fucosidosis;MRIand MRS findings. Pediatr Radiol 37:1050-1052, 2007.

29) Tsuji, M., Aida, N., Obata, T., et al.:A new case of GABA transaminase deficiency facillitated by proton MR spectroscopy.J Inherit Metab Dis 33:85-90, 2010.

30) Ethofer, T., Seeger, U., Klose, U., et al.:Proton MR spectroscopyin succinic semialdehyde dehydrogenase deficiency.Neurology 62:1016-1018, 2004.

31) Yalcinkaya, C., Dincer, A., Gunduz, E., et al.:MRI and MRS in HMG-CoA lyase deficiency. Pediatr Neurol 20:375-380, 1999.
pubmed

32) Cecil, K.M., Kos, R.S.:Magnetic resonance spectroscopyand metabolic imaging in white matter diseases and pediatricdisorders. Top Magn Reson Imaging 17:275-293, 2006.

33) Van der Voorn, J.P., Pouwels, P.J., Hart, A.A., et al.:Childhoodwhite matter disorders;Quantitative MR imaging andspectroscopy. Radiology 241:510-517, 2006.

34) Henefeld, F.A., Brockmann, K., Pouwels, P.J.W., et al.:Quantitative proton MRS of Pelizaeus-Merzbacher disease. Evidence of dys-and hypomyelination. Neurology 65:701-706, 2005.

35) Takanashi, J., Saito, S., Aoki, I., et al.:Increased N-acetylaspartate in model mouse of pelizaeus-Merzbacher disease.J Magn Reson Imaging 35:418-425, 2012.
pubmed

36) Wofl, N.I., Willemsen, M.A.A.P., Engekle, U.F., et al.:Severe hypomyelination associated with increased levelsof N-acetyaspartylglutamate in CSF. Neurology 62:1503-1508, 2004.

37) Van der Knaap, M.S., Naidu, S., Pouwels, P.J.W., et al.:New syndrome characterized by hypomyelination with atrophyof the basal ganglia and cerebellum. Am J Neuroradiol 23:1466-1474, 2002.

38) Oz, G., Tkac, I., Charnas, L.R., et al.:Assessment of adrenoleukodystrophylesions by high field MRS in non-sedatedpediatric patients. Neurology 64:434-441, 2005.
pubmed

39) Brockmann, K., Dechent, P., Wilken, B., et al.:Proton MRSprofile of cerebral metabolic abnormalities in Krabbe disease.Neurology 60:819-825, 2003.
pubmed

40) Brockmann, K., Dechenjt, P., Meins, M., et al.:Cerebralproton magnetic resonance spectroscopy in infantile Alexanderdisease. J Neurol 250:300-306, 2003.

41) Takanashi, J., Sugita, K., Tanabe, Y., et al.:Adolescentcase of Alexander disease;MR imaging and MR spectroscopy.Pediatr Neurol 18;67-70, 1998.

42) Sitter, B., Autti, T., Tyynela, J., et al.:High-resolutionmagic angle spinning and 1H magnetic resonanace spectroscopyreveal significantly altered neuronal metabolite profilesin CLN1 but not in CLN3. J Neurosci Res 77:762-769,2004.

43) Van der Knaap, M.S., Barth, P.G., Gabreels, F.J.M., et al.:A new leukoencephalopathy with vanishing white matter.Neurology 48:845-855, 1997.

44) Moller, H.E., Kurlemann, G., Putzler, M., et al.:Magnetic resonance spectroscopy in patients with MELAS. J Neurol Sci 229-230:131-139, 2005.

45) Takanashi, J., Sugita, K., Tanabe, Y., et al.:Dichloroacetatetreatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci 145:83-6, 1997.
pubmed

46) Scheper ,G.C., van der Klok, T., van Andel, R., et al.:Mitochondrial aspartyl-tRNA synthetase deficiency causesleukoencephalopathy with brain stem and spinal cord involvementand lactate elevation. Nat Genet 39:534-539, 2007.

47) Van der Knaap, M.S., Van der Voorn, P., Barkhof, F., etal.:A new encephalopathy with brainstema and spinal cordinvolvement and high lactate. Ann Neurol 53:252-258,2003.

48) Linnankivi, T., Lundbom, N., Autti, T., et al.:Five new cases of a recently described leukoencephalopathy with highbrain lactate. Neurology 63:688-692, 2004.

P.211 掲載の参考文献

1) Lundbom, N., Barnett, A., Bonavita, S., et al.:MR image segmentation and tissue metabolite contrast in 1H spectroscopicimaging of normal and aging brain. Magn Reson Med 41:841-845, 1999.

2) Brooks, J.C., Roberts, N., Kemp, G.J., Gosney, M.A., Lye,M., Whitehouse, G.H.:A proton magnetic resonance spectroscopystudy of age-related changes in frontal lobe metaboliteconcentrations. Cereb Cortex 11:598-605, 2001.

3) Schuff, N., Amend, D.L., Knowlton, R., Norman, D., Fein, G.,Weiner, M.W.:Age-related metabolite changes and volumeloss in the hippocampus by magnetic resonance spectroscopyand imaging. Neurobiol Aging 20:279-285, 1999.

4) Harada, M., Miyoshi, H., Otsuka, H., Nishitani, H., Uno, M.:Multivariate analysis of regional metabolic differences innormal ageing on localised quantitative proton MR spectroscopy.Neuroradiology 43:448-452, 2001.

5) Minati, L., Grisoli, M., Bruzzone, M.G.:MR spectroscopy,functional MRI, and diffusion-tensor imaging in the agingbrain;A conceptual review. J Geriatr Psychiatry Neurol 20:3-21, 2007.

6) Chang, L., Ernst, T., Poland, R.E., DJ J.:In vivo proton magnetic resonance spectroscopy of the normal aging humanbrain. Life Sci 58:2049-2056, 1996.

7) Kaiser, L.G., Schuff, N., Cashdollar, N., Weiner, M.W.:Agerelatedglutamate and glutamine concentration changes innormal human brain;1H MR spectroscopy study at 4 T. Neurobiol Aging 26:665-672, 2005.

8) Oberg, J., Spenger, C., Wang, F.H., et al.:Age relatedchanges in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29:1423-1433, 2008.

9) Charlton, R.A., Barrick, T.R., McIntyre, D.J., et al.:White matter damage on diffusion tensor imaging correlates withage-related cognitive decline. Neurology 66:217-222,2006.

10) Charlton, R.A., Schiavone, F., Barrick, T.R., Morris, R.G.,Markus, H.S.:Diffusion tensor imaging detects age relatedwhite matter change over a 2 year follow-up which is associatedwith working memory decline. J Neurol Neurosurg Psychiatry 81:13-19, 2009.

11) Lorenzo-Lopez, L., Amenedo, E., Pazo-Alvarez, P., Cadaveira,F.:Visual target processing in high-and low-performingolder subjects indexed by P3 component. Neurophysiol Clin 37:53-61, 2007.
pubmed

12) Heuninckx, S., Wenderoth, N., Debaere, F., Peeters, R.,Swinnen, S.P.:Neural basis of aging:The penetration ofcognition into action control. J Neurosci 25:6787-6796,2005.
pubmed

13) Gutchess, A.H., Hebrank, A., Sutton, B.P., et al.:Contextualinterference in recognition memory with age. Neuro Image 35:1338-1347, 2007.

14) Nakai, T., Bagarinao, E., Miyakoshi, M., Yoshida, M., Matsuo,K.:The Hemodynamic response function represents theneuronal Basis of Demand-Reservation Balance in Again Brain. Proceedings of The 2009 International Symposium on Early Detection and Rehabilitation Technology of Dementia 85-88, 2009.

15) Chantal, S., Labelle, M., Bouchard, R.W., Braun, C.M.,Boulanger, Y.:Correlation of regional proton magnetic resonancespectroscopic metabolic changes with cognitive deficitsin mild Alzheimer disease. Arch Neurol 59:955-962,2002.

16) Dixon, R.M., Bradley, K.M., Budge, M.M., Styles, P., Smith,A.D.:Longitudinal quantitative proton magnetic resonancespectroscopy of the hippocampus in Alzheimer:s disease.Brain 125 (Pt 10):2332-2341, 2002.

17) Jessen, F., Block, W., Traber, F., et al.:Proton MR spectroscopydetects a relative decrease of N-acetylaspartate inthe medial temporal lobe of patients with AD. Neurology 55:684-688, 2000.

18) Adalsteinsson, E., Sullivan, E.V., Kleinhans, N., Spielman,D.M., Pfefferbaum, A.:Longitudinal decline of the neuronalmarker N-acetyl aspartate in Alzheimer:s disease. Lancet 355 (9216):1696-1697, 2000.

19) Kantarci, K., Weigand, S.D., Petersen, R.C., et al.:Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer:s disease. Neurobiol Aging 28:1330-1339, 2007.
pubmed

20) Ernst, T., Chang, L., Melchor, R., Mehringer, C.M. .:Mehringer,Frontotemporal dementia and early Alzheimer disease;Differentiation with frontal lobe H-1 MR spectroscopy.Radiology 203:829-836, 1997.
pubmed

21) Griffith, H.R., den Hollander, J.A., Stewart, C.C., et al.:Elevated brain scyllo-inositol concentrations in patients with Alzheimer:s disease. NMR Biomed 20:709-716, 2007.
pubmed

22) Herminghaus, S., Frolich, L., Gorriz, C., et al.:Brain metabolismin Alzheimer disease and vascular dementia assessedby in vivo proton magnetic resonance spectroscopy. Psychiatry Res 123:183-190, 2003.

23) Kantarci, K., Reynolds, G., Petersen, R.C., et al.:Proton MR spectroscopy in mild cognitive impairment and Alzheimerdisease:comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 24:843-849, 2003.

24) Moats, R.A., Ernst, T., Shonk, T.K., Ross, B.D.:Abnormalcerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32:110-115, 1994.
pubmed

25) Catani, M., Mecocci, P., Tarducci, R., et al.:Protonmagnetic resonance spectroscopy reveals similar whitematter biochemical changes in patients with chronichypertension and early Alzheimer:s disease. J Am Geriatr Soc 50:1707-1710, 2002.

26) Rose, S.E., de Zubicaray, G.I., Wang, D., et al.:A 1HMRS study of probable Alzheimer:s disease and normalaging;Implications for longitudinal monitoring of dementiaprogression. Magn Reson Imaging 17:291-299, 1999.

27) Parnetti, L., Tarducci, R., Presciutti, O., et al.:Protonmagnetic resonance spectroscopy can differentiate Alzheimer:s disease from normal aging. Mech Ageing 97:9-14, 1997.

28) Griffith, H.R., Hollander, J.A., Okonkwo, O., et al.:Executive function is associated with brain proton magneticresonance spectroscopy in amnestic mild cognitiveimpairment. J Clin Exp Neuropsychol 29:599-609, 2007.

29) Kaiser, L.G., Schuff, N., Cashdollar, N., Weiner, M.W.:Scyllo-inositol in normal aging human brain:1H magneticresonance spectroscopy study at 4 Tesla. NMR Biomed 18:51-55, 2005.

30) MacKay, S., Ezekiel, F., Di Sclafani, V., et al.:Alzheimerdisease and subcortical ischemic vascular dementia;Evaluation by combining MR imaging segmentation and H-1MR spectroscopic imaging. Radiology 198:537-545, 1996.

31) Lazeyras, F., Charles, H.C., Tupler, L.A., Erickson, R.,Boyko, O.B., Krishnan, K.R.:Metabolic brain mapping in Alzheimer:s disease using proton magnetic resonance spectroscopy. Psychiatry Res 82:95-106, 1998.
pubmed

32) Chantal, S., Braun, C.M., Bouchard, R.W., Labelle, M.,Boulanger, Y.:Similar 1H magnetic resonance spectroscopicmetabolic pattern in the medial temporal lobes of patientswith mild cognitive impairment and Alzheimer disease. Brain Res 1003:26-35, 2004.

33) Griffith, H.R., Stewart, C.C., den Hollander, J.A.:Protonmagnetic resonance spectroscopy in dementias and mildcognitive impairment. Int Rev Neurobiol 84:105-131, 2009.

34) Pfefferbaum, A., Adalsteinsson, E., Spielman, D., Sullivan,E.V., Lim, K.O.:In vivo brain concentrations of N-acetylcompounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 56:185-192, 1999.

35) Kantarci, K., Xu, Y., Shiung, M.M., et al.:Comparativediagnostic utility of different MR modalities in mild cognitiveimpairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14:198-207, 2002.

36) Waldman, A.D., Rai, G.S.:The relationship between cognitive impairment and in vivo metabolite ratios inpatients with clinical Alzheimer's disease and vasculardementia;A proton magnetic resonance spectroscopy study.Neuroradiology 45:507-512, 2003.

37) Kantarci, K., Knopman, D.S., Dickson, D.W., et al.:Alzheimer disease;Postmortem neuropathologic correlates ofantemortem 1H MR spectroscopy metabolite measurements.Radiology 248:210-220, 2008.
pubmed

38) Petersen, R.C., Doody, R., Kurz, A., et al.:Currentconcepts in mild cognitive impairment. Arch Neurol 58:1985-1992, 2001.
pubmed

39) Franczak, M., Prost, R.W., Antuono, P.G., Mark, L.P., Jones, JL.Ulmer, J.L.:Proton magnetic resonance spectroscopy of thehippocampus in patients with mild cognitive impairment;A pilot study. J Comput Assist Tomogr 31:666-670, 2007.

40) Ackl, N., Ising, M., Schreiber, Y.A., Atiya, M., Sonntag,A., Auer, D.P.:Hippocampal metabolic abnormalities in mildcognitive impairment and Alzheimer:s disease. Neurosci Lett 384:23-28, 2005.

41) Garcia Santos, J.M., Gavrila, D., Antunez, C., et al.:Magnetic resonance spectroscopy performance for detectionof dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. Dement Geriatr Cogn Disord 26:15-25, 2008.

42) Kantarci, K., Jack C.R, Jr., Xu, Y.C., et al.:Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease;A 1H MRS study. Neurology 55:210-217, 2000.
pubmed

43) Catani, M., Cherubini, A., Howard, R., et al.:(1) H-MR spectroscopy differentiates mild cognitive impairment fromnormal brain aging. Neuroreport 12:2315-2317, 2001.

44) Rami, L., Gomez-Anson, B., Bosch, B., et al.:Cortical brain metabolism as measured by proton spectroscopy is related tomemory performance in patients with amnestic mild cognitive impairment and Alzheimer:s disease. Dement Geriatr Cogn Disord 24:274-279, 2007.
pubmed

45) Modrego, P.J., Fayed, N., Pina, M.A.:Conversion from mild cognitive impairment to probable Alzheimer:s diseasepredicted by brain magnetic resonance spectroscopy. Am JPsychiatry 162:667-675, 2005.

46) Metastasio, A., Rinaldi, P., Tarducci, R., et al.:Conversionof MCI to dementia:Role of proton magnetic resonancespectroscopy. Neurobiol Aging 27:926-932, 2006.

47) Kantarci, K., Petersen, R.C., Boeve, B.F., et al.:1H MR spectroscopy in common dementias. Neurology 63:1393-1398, 2004.
pubmed

48) Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., Del Tredici, K.:Stages in the development of Parkinson:sdisease-related pathology. Cell Tissue Res 318:121-134,2004.

49) Griffith, H.R., den Hollander, J.A., Okonkwo, O.C., O:Brien,T., Watts, R.L., Marson, D.C.:Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.Alzheimers Dement 4:421-427, 2008.
pubmed

50) Griffith, H.R., Okonkwo, O.C., O'Brien, T., Hollander,J.A.:Reduced brain glutamate in patients with Parkinson'sdisease. NMR Biomed 21:381-387, 2008.

51) Coulthard, E., Firbank, M., English, P., et al.:Protonmagnetic resonance spectroscopy in frontotemporaldementia. J Neurol 253:861-868, 2006.

52) Mueller, S.G., Schuff, N., Weiner, M.W.:Evaluation of treatment effects in Alzheimer:s and other neurodegenerativediseases by MRI and MRS. NMR Biomed 19:655-668,2006.

P.217 掲載の参考文献

1) Neubauer, S.:The failing heart-an engine out of fuel. N Engl J Med 356:1140-1151, 2007.
pubmed

2) Opie, L.H.:Mechanisms of cardiac contraction and relaxation.Braunwald's Heart Disease. 8th ed. Saunders Elsevier509-540, 2008.

3) Bottomley, P.A., Foster, T.B., Darrow, R.D.:Depth-resolved surface coil spectroscopy (DRESS) or in vivo 1H, 31P, and 13C NM1R. J Magn Reson 59:338-342, 1984.

4) Ordidge, R.J., Connelly, A,. Lohman, J.A.B.:Image-selected in vivo spectroscopy (ISIS) ; A new technique for spatiallyselective NMR spectroscopy. J Magn Reson 66:283-294,1985.

5) Pohmann, R., von Kienlin, M.:Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 45:817-826, 2001.
pubmed

6) Neubauer, S.:Cardiac magnetic resonance spectroscopy; Established and emerging applications:London, United Kingdom. Taylor and Francis Group LLC, 2003.

7) Bottomley, P.A., Atalar, E., Weiss, R.G.:Human cardiac high energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 35:664-670, 1996.

8) Meininger, M., Landschutz, W., Beer, M., et al.:Concentrations of human cardiac phosphorus metabolites determinedby SLOOP 31P NMR spectroscopy. Magn Reson Med. 41:657-663, 1999.

9) Eisenberg, E., Hill, T.L.:Muscle contraction and free energytransduction in biological systems. Science 227:999-1006,1985.

10) Opie, L.H.:Division of ATP utilization. The Heart ; Physiology and metabolism, 2nd ed. Raven Press, New York, 261,1991.

11) Rayment, I., Holden, H.M., Whittaker, M., et.al.:Structureof the actin-myosin complex and its implications for musclecontraction. Science 261:58-65, 1993.

12) Bessman, S.P., Geiger, P.J.:Transport of energy in muscle.Science 211:448-452, 1981.

13) Kammermeier, H.:Why do cells need phophocreatine and a phosphocreatine shuttle. J Mol Cell Cardiol 19:115-118,1987.

14) Opie, L.H.:Cardiac metabolism-emergence, decline, and resurgence, Part 1. Cardiovasc Res 26:721-733, 1992.

15) Iwai-Kanai, E., Hasegawa, K., Sawamura, T., et al.:Activation of lectin-like oxidized low density lipoprotein receptor-1induces apoptosis in cultured neonatal rat cardiac myocytes.Circulation 104:2948-2954, 2001.
pubmed

16) Iwai-Kanai, E., Hasegawa, K., Adachi, S., et al.:Effects of endothelin-1 on mitochondrial function during the protection against myocardial cell apoptosis. Biochem Biophys Res Commun 305:898-903, 2003.
pubmed

17) Bottomley, P.A.:Non invasive study of high-energy phosphatemetabolism in human heart by depth-resolved 31P NMRspectroscopy. Science 229:769-772, 1985.

18) Blackledgw, M.J., Rajagopalan, B., Oberhaensli, R.D., etal.:Quantitative studies of human cardiac metabolism by 31P rotating frame NMR. Proc Natl Acad Sci USA 84:4283,1987.

19) Sardanelli, F., Quarenghi, M.:MR spectroscopy of the heart. Radiol Med 111:1025-1034, 2006.
pubmed

20) Lamb, H.J., Doornbos, J., den Hollander, J.A., et al.:Reproducibility of human cardiac 31P-NMR spectroscopy. NMRBiomed 9:217-227, 1996.
pubmed

21) Kostler, H., Landschutz, W., Koeppe, S., et al.:Age and gender dependence of human cardiac phosphorus metabolitesdetermined by SLOOP 31P MR spectroscopy. Magn Reson Med 56:907-911, 2006.
pubmed

22) Bottomley, P.A.:MR spectroscopy of the human heart:thestatus and the challenges. Radiology , 191:593-612, 1994.

23) Bottomley, P.A., Weiss, R.G.:Noninvasive localized MR quantification of creatine kinase metabolites in normaland infracted carnine myocardium. Radiology , 219:411-418,2001.

24) Lewandowski, E.D., Doumen, C., White, L.T., et al.:Multiplestructure of 13C NMR signal from glutamate and directdetection of tricarboxylic acid (TCA) cycle intermediates.Magn Reson Med , 35:149-154, 1996.

25) Clarke, K., O:Connor, A.J., Willis, R.J.:Temporal relation between energy metabolism and myocardial function duringischemia and reperfusion. Am J Physiol 253:H412-421,1987.

26) Weiss, R.G., Bottomley, P.A., Hardy, C.J., et al.:Regionalmyocardial metabolism of high-energy phosphates duringisometric exercise in patients with coronary artery disease. NEngl J Med 323:1593-1600, 1990.

27) Buchthal, S.D., den Hollander, J.A., Merz, C.N., et al.:Abnormal myocardial phosphorus-31 nuclear magnetic resonancespectroscopy in woman with chest pain but normalcoronary angiograms. N Engl J Med 342:829-835, 2000.

28) Johnson, B.D., Shaw, L.J., Buchthal, S.D., et al.:Prognosisin woman with myocardial ischemia in the absenceof obstructive coronary disease:results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Woman's Ischemia Syndrome Evaluation (WISE) .Circulation 109:2993-2999, 2004.

29) Friedrich, J., Apstein, C.S., Ingwall, J.S., et al.:31P nuclearmagnetic resonance spectroscopic imaging of regions ofremodeled myocardium in the infracted rat heart. Circulation 92:3527-3538, 1995.

30) Yabe, T., Mitsunami, K., Inubbushi, T., et al.:Quantitativemeasurements of cardiac phosphorus metabolites in coronaryartery disease by 31P ,magnetic resonance spectroscopy. Circulation 92:15-23, 1995.

31) Bottomley, P.A., Weiss, R.G.:Non-invasive magnetic-resonancedetection of creatine depletion in non-viable infractedmyocardium. Lancet 351:714-718, 1998.

32) Sandstede, J.J., Hillenbrand, H., Beer, M., et al.:Timecourse of 23Na signal intensity after myocardial infarction inhumans. Magn Reson Med 52:545-551, 2004.

33) Neubauer, S., Krahe, T., Schindler, R., et al.:31P magneticresonance spectroscopy in dilated cardiomyopathy and coronaryartery disease. Altered cardiac high-energy phosphatemetabolism in heart failure. Circulation 86:1810-1818,1992.

34) Conway, M.A., Allis, J., Ouwerkerk, R., et al.:Detectionof low phosphocreatine to ATP ratio in failing hypertrophiedhuman myocardium by 31P magnetic resonance spectroscopy.Lancet 338:973-976, 1991.

35) Beyerbacht, H.P., Lamb, H.J., van DerLaarse, A., et al.:Aortic valve replacement in patients with aortic valve stenosisimproves myocardial metabolism and diastolic function.Radiology 219:637-643, 2001.

36) Beer, M., Seyfarth, T., Sandstede, J., et al.:Absolute concentrationsof high-energy phosphate metabolites in normal,hypertrophied, and failing human myocardium measurednoninvasively with 31P-SLOOP magnetic resonance spectroscopy.J Am Coll Cardiol 40:1267-1274, 2002.

37) Chidsey, C.A., Weinbach, E.C., Pool, P.E., et al.:Biochemicalstudies of energy production of the human failing heart. JClin Invest 45:40, 1966.

38) Weiss, R.G., Gerstenblith, G., Bottomley, P.A.:ATP fluxthrough creatine kinase in the normal, stressed, and failinghuman heart. Proc Natl Acad Sci USA 102:808-813, 2005.
pubmed

39) Smith C.S, Bottomley P.A, Schulman S.P, et al.:Alteredcreatine kinase adenosine triphosphate kinetics in failinghypertrophied human myocardium. Circulation 114:1151-1158, 2006.

40) Beer, M., Wagner, D., Myers, J., et al.:Effects of exercisetraining on myocardial energy metabolism and ventricularfunction assessed by quantitative phosphorus-31 magneticresonance imaging in dilated cardiomyopathy. J Am Coll Cardiol 51:1883-1991, 2008.

41) Scheuermann-Freestone, M., Madsen, P.L., Manners, D.,et al.:Abnormal cardiac and skeletal muscle energy metabolismin patients with type 2 diabetes. Circulation 107:3040-3046, 2003.

42) Gavock, J.M., Lingvay, I., Zib, I., et al.:Cardiac steatosisin diabetes mellitus; A 1H-magnetic resonance spectroscopystudy. Circulation 116:1170-1175, 2007.

43) Merritt, M.E., Harrison, C., Storey, C., et al.:Hyperpolarized 13C allows a direct measure of flux through a singleenzyme-catalyzed step by NMR. Proc Natl Acad Sci USA 104:10773-19777, 2007.

43) Merritt, M.E., Harrison, C., Storey, C., et al.:Hyperpolarized C allows a direct measure of flux through a sing

44) Gallagher, F.A., Kettunen, M.I., Day, S.E., et al.:Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453:940-943, 2008.
pubmed

P.229 掲載の参考文献

1) Oberhaensli, R.D., Galloway, G.J., Taylor, D.J., et al.:Assessment of human liver metabolism by phosphorus-31magnetic resonance spectroscopy. Br J Radiology 59:695-699, 1986.

2) Chary K.V.R., Govil, G.:NMR in Biological Systems. Springer,The Netherlands, 426-429, 2008.

3) Imamura, H., Huynh Nhat, K.P., Togawa H, et al.:visualizationof ATP levels inside single living cells with fluorescenceenergy transfer-based genetically encoded indicators.PNAS Early Edition (www.pnas.org/cgi/doi/10.1073/pnas.0904764106) .

4) Schmid, A.I., Chmelik, M., Szendroedi, J., et al.:Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magetization transfer experiment.NMR Biomed 21:437-443, 2008.
pubmed

5) 三森文行:スピンのふるまい. MRIレクチャー基礎から学ぶMRI. 日本磁気共鳴医学会教育委員会編, 東京, インナービジョン, 21, 2001.

6) Gallis J.L & Canioni, P.:MRS of the liver. Magnetic Resonance Spectroscopy in Biology and Medicine (Ed. de Certaines JD, Boveee WMMJ & Podo F), Pergamon Press, UK,345-368, 1992.

7) Gadian, D.G.:NMR and its Application to Loving Systems. Oxford, Oxford Science Publications, 188-189, 1995.

8) Leach, M., le Moyec, L., & Podo, F.:MRS of tumors;Basicprinciples. Magnetic Resonance Spectroscopy in Biology and Medicine (Ed. de Certaines JD, Boveee WMMJ & Podo F),Pergamon Press, UK, 295-344, 1992.

9) Prichard, J.W., & Schulman, R.G.:NMR spectroscopy ofbrain metabolism in vivo . Ann Rev Neuroscience 9:61-85,1986.

10) Ordidge, R.J., Connelly, A,. & Lohman, J.A.B.:Imageselectedin vivo spectroscopy (ISIS); A new technique forspatially selective NMR spectroscopy. J Mag Res 66:283-294, 1986.

11) Buchli, R., Meier, D., Martin, E., et al.:Assessment ofabsolute metabolite concentrations in human tissue by 31PMRS in vivo . Part II:Muscle, liver, kidney. Mag Reson Med 32:453-458, 1994.

12) Gyulai, L., Bolinger, L., Leigh, J.S., et al.:Phophoethanolamine-the major constituents of the phosphomonoesterpeak observed by 31P-NMR on developing dog brain. FEBSLetter 178:137-142, 1984.

13) Luyten, P.R., Bruntink, G., Sloff, F.M., et al.:Broadband proton decoupling in human 31P NMR spectroscopy. NMR in Biomed 1:177-183, 1989.
pubmed

14) Navon, G., Ogawa, S., Shulman, R.G., et al.:31P nuclear magnetic resonance studies of Ehrlich ascites tumor cells.Proc Natl Acad Sci, USA, 74:87-91, 1977.
pubmed

15) 佐伯光明, 蘆田浩, 今村惠子・他:悪性肝腫瘍に対する31P-MRSの臨床応用-治療経過の判定を中心に. 日本医学放射線学会雑誌, 52:744-754, 1992.

16) 今村惠子, 佐伯光明編著:生体磁気共鳴スペクトル・ライブラリ・石川徹監修, 東京, アイピーシー, 1996.0

17) Cady, E.B.:MRS of the newborn human infant. Magnetic Resonance Spectroscopy in Biology and Medicine (Ed. de Certaines JD, Boveee WMMJ & Podo F), 437-477, UK, Pergamon Press, 1992.

18) Lim, A.K.P., Khan, S.A., Cox, I.J., et al.:Nuclear magneticresonance spectroscopy in the study of human liver. Nuclear Magnetic Spectroscopy in the Study of Neoplastic Tissue (Ed:Tosi R & Tugnoli V) . Nova Science Publishers, New Work, 295-311, 2005.

19) Paul, C.R., Milestone, B.M., & Lenkinski, R.E.:Clinical MRS studies of the liver and spleen. MR Spectroscopy-clinical applications and techniques (Ed:Young IR & Charles HC) . Martin Dunitz Ltd. London, 105-138, 1996.

20) Lim, A.K., Patel, N., Hamilton, G., et al.:The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 37:788-794, 2003.
pubmed

21) Dezortova, M., Taimr, P., Skoch, A., et al.:Etiokogy andfunctional status of liver cirrhosis by 31P MR spectroscopy.World J Gastroenterol 11:6926-6931, 2005.

22) Noren, B., Dahlqvist, O., Lundberg, P., et al.:Separationof advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance sepctroscopy. Eur J Radiol 66:313-320, 2008.

23) 福村玲子, 名越温古, 野田珠美・他:Phosphorus-31 magneticresonance spectroscopyにより肝臓への臓器浸潤を推定し得た急性リンパ性白血病の1例. 聖マリアンナ医科大学雑誌, 24:544-550, 1996.

24) Heindel, W., du Mesnil de Rochemont, R., Hugel, H., et al.:31P-MR spectroscopy of the human lover-the spectral indicationsof lymphoma infiltration. Rofo 167:62-70, 1997.

P.237 掲載の参考文献

1) Bergstrom, J.:Muscle electrolytes in man. Scand J Clin Lab Invest (suppl) 68:1-110, 1962.

2) Boesch, C.:Magnetic resonance spectroscopy;Basic principles.In:Edelman R.R., Hesselink J.R., Zlatkin M.B., Crues J.V., editors. Clinical magnetic resonance imaging. 3rd ed.Philadelphia, PA:Saunders, Elsevier:459-492, 2005.

3) Boska, M.D., Nelson, J.A., Sripathi, N., et al.:31P MRS studiesof exercising human muscle at high temporal resolution.Magn Reson Med 41:1145-1151, 1999.

4) Taylor, D.J., Bore, P.J., Styles, D.G., et al.:Bioenergeticsof intact human muscle;A 31P nuclear magnetic resonancestudy. Mol Biol Med 1:77-94, 1983.

5) Hamaoka, T., Iwane, H., Shimomitsu, T., et al.:Noninvasive measures of oxidative metabolism on working humanmuscles by near-infrared spectroscopy. J Appl Physiol 81:1410-1417, 1996.
pubmed

6) Walker, P.M., Brunotte, F., Rouhier-Marcer, I., et al.:Nuclearmagnetic resonance evidence of different muscular adaptationsafter resistance training. Arch Phys Med Rehabil 79:1391-1398, 1998.

7) Kreis, R., Kamber, M., Koster, M., et al.:Creatine supplementation-part II:in vivo magnetic resonance spectroscopy.Med Sci Sports Exerc 31:1770-1777, 1999.

8) McCully, K.K., Boden, B.P., Tuchler, M., et al.:Wrist flexormuscles of elite rowers measured with magnetic resonancespectroscopy. J Appl Physiol 67:926-932, 1989.

9) McCully, K.K., Fielding, R.A., Evans, W.J., et al.:Relationshipsbetween in vivo and in vitro measurements of metabolismin young and old human calf muscles. J Appl Physiol 75:813-819, 1993.

10) Kemp, GJ., Taylor, DJ., Radda, GK., et al.:Bio-energeticchanges in human gastrocnemius muscle 1-2 days afterstrenuous exercise. Acta Physiol Scand 146:11-14, 1992.
pubmed

11) Yanagisawa, O., Niitsu, M., Takahashi, H., et al.:Evaluationsof cooling exercised muscle with MR imaging and 31PMR spectroscopy. Med Sci Sports Exerc 35:1517-1523,2003.

12) Maurer, J., Konstanczak, P., Sollner, O., et al.:Musclemetabolism of professional athletes using 31P-spectroscopy.Acta Radiol 40:73-77, 1999.

13) Bernus, G., Gonzalez de Suso, J.M., Alonso, J., et al.:31P MRS of quadriceps reveals quantitative differences betweensprinters and long-distance runners. Med Sci Sports Exerc 25:479-484, 1993.
pubmed

14) Ross, B.D., Radda, G.K., Gadian, D.G., et al.:Examination of a case of suspected McArdle:s syndrome by 31P nuclearmagnetic resonance. N Engl J Med 304:1338-1342, 1981.

15) Gruetter, R., Kaelin, P., Boesch, C., et al.:Non-invasive 31P magnetic resonance spectroscopy revealed McArdle diseasein an asymptomatic child. Eur J Pediatr 149:483-486,1990.

16) Lodi, R., Kemp, GJ., Muntoni, F., et al.:Reduced cytosolicacidification during exercise suggests defective glycolyticactivity in skeletal muscle of patients with Becker musculardystrophy;An in vivo 31P magnetic resonance spectroscopystudy. Brain 122:121-130, 1999.

17) Isbell, D.C., Berr, S.S., Toledano, A.Y., et al.:Delayed calfmuscle phosphocreatine recovery after exercise identifiesperipheral arterial disease. J Am Coll Cardiol 47:2289-2295, 2006.

18) Kuhl, C.K., Layer, G., Traber, F., et al.:Mitochondrialencephalomyopathy:correlation of P-31 exercise MR spectroscopywith clinical findings. Radiology 192:223-230,1994.

19) Cea, G., Bendahan, D., Manners, D., et al.:Reduced oxidativephosphorylation and proton efflux suggest reducedcapillary blood supply in skeletal muscle of patients with dermatomyositisand polymyositis;A quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 125:1635-1645, 2002.

20) Penn, A.M., Roberts, T., Hodder, J., et al.:Generalizedmitochondrial dysfunction in Parkinson:s disease detected bymagnetic resonance spectroscopy of muscle. Neurology 45:2097-2099, 1995.
pubmed

21) Schick, F., Eismann, B., Jung, W.I., et al.:Comparison oflocalized proton NMR signals of skeletal muscle and fat tissuein vivo:two lipid compartments in muscle tissue. Magn Reson Med 29:158-167, 1993.

22) Boesch, C., Slotboom, J., Hoppeler, H., et al.:In vivodetermination of intra-myocellular lipids in human muscle bymeans of localized 1H-MR-spectroscopy. Magn Reson Med 37:484-493, 1997.

23) Rico-Sanz, J., Moosavi, M., Thomas, EL., et al.:In vivoevaluation of the effects of continuous exercise on skeletalmuscle triglycerides in trained humans. Lipids 35:1313-1318, 2000.

24) Torriani, M., Thomas, B.J., Halpern, E.F., et al.:Intramyocellularlipid quantification:repeatability with 1H MR spectroscopy.Radiology 236:609-614, 2005.
pubmed

25) Goodpaster, B.H., He, J., Watkins, S., et al.:Skeletal musclelipid content and insulin resistance:evidence for a paradoxin endurance-trained athletes. J Clin Endocrinol Metab 86:5755-5761, 2001.

26) Ozdemir, MS., Reyngoudt, H., De Deene, Y., et al.:Absolutequantification of carnosine in human calf muscle byproton magnetic resonance spectroscopy. Phys Med Biol 52:6781-6794, 2007.

27) Meyerspeer, M., Kemp, GJ., Mlynarik, V., et al.:Direct noninvasivequantification of lactate and high energy phosphatessimultaneously in exercising human skeletal muscle by localizedmagnetic resonance spectroscopy. Magn Reson Med 57:654-660, 2007.

28) Kreis, R., Bruegger, K., Skjelsvik, C., et al.:Quantitative 1H magnetic resonance spectroscopy of myoglobin de-andreoxygenation in skeletal muscle;reproducibility and effectsof location and disease. Magn Reson Med 46:240-248,2001.

29) Tran, T.K., Sailasuta, N., Hurd, R., et al.:Spatial distributionof deoxymyoglobin in human muscle:an index of localtissue oxygenation. NMR Biomed 12:26-30, 1999.

30) Yoshioka, Y., Oikawa, H., Ehara, S., et al.:Noninvasivemeasurement of temperature and fractional dissociation ofimidazole in human lower leg muscles using 1H-nuclear magneticresonance spectroscopy. J Appl Physiol 98:282-287,2005.

31) Avison, M.J., Rothman, D.L., Nadel, E., et al.:Detectionof human muscle glycogen by natural abundance 13C NMR.Proc Natl Acad Sci USA 85:1634-1636, 1988.

32) Goforth, H.W. Jr., Laurent, D., Prusaczyk, W.K., et al.:Effects of depletion exercise and light training on muscle glycogensupercompensation in men. Am J Physiol Endocrinol Metab 285:E1304-1311, 2003.
pubmed

33) Van Den Bergh, A.J., Houtman, S., Heerschap, A., et al.:Muscle glycogen recovery after exercise during glucoseand fructose intake monitored by 13C-NMR. J Appl Physiol 81:1495-1500, 1996.

34) Price, T.B., Krishnan-Sarin, S., Rothman, D.L.:Smokingimpairs muscle recovery from exercise. Am J Physiol Endocrinol Metab 285:E116-122, 2003.
pubmed

P.244 掲載の参考文献

1) Costello, L.C., Franklin, R.B.:Concepts of citrate productionand secretion by prostate;1. metabolic relationships.Prostate 18:25-46, 1991.

2) Lynch, M.J., Masters, J., Pryor, J.P., Lindon, J.C., Spraul, M.,Foxall, P.J., Nicholson, J.K.:Ultra high field NMR spectroscopicstudies on human seminal fluid, seminal vesicle andprostatic secretions. J Pharm Biomed Anal 12:5-19, 1994.

3) Umbehr, M., Bachmann, L.M., Held, U., et al.:Combinedmagnetic resonance imaging and magnetic resonancespectroscopy imaging in the diagnosis of prostate cancer;Asystematic review and meta-analysis. Eur Urol 55:575-590, 2009.

4) Males, R.G., Vigneron, D.B., Star-Lack, J., et al.:Clinicalapplication of BASING and spectral/spatial water and lipidsuppression pulses for prostate cancer staging and localizationby 3D H magnetic resonance spectroscopic imaging.Magn Reson Med 43:17-22, 2000.

5) Schricker, A.A., Pauly, J.M., Kurhanewicz, J., et al.:Dualbandspectral-spatial RF pulses for prostate MR spectroscopicimaging. Magn Reson Med 46:1079-1087, 2001.

6) Mescher, M., Merkle, H., Kirsch, J., et al.:Simultaneous invivo spectral editing and water suppression. NMR Biomed 11:266-272, 1998.

7) Kaji, Y., Wada, A., Imaoka, I., et al.:Proton two-dimensionalchemical shift imaging for evaluation of prostate cancer;External surface coil vs. endorectal surface coil. J Magn Reson Imaging 16:697-706, 2002.

8) Lichy, M.P., Pintaske, J., Kottke, R., et al.:3D proton MRspectroscopic imaging of prostate cancer using a standardspine coil at 1.5T in clinical routine; A feasibility study.European Radiology 15:653-660, 2005.

9) Kaji, Y., Kuroda, K., Maeda, T., et al.:Anatomical andmetabolic assessment of prostate using a 3-Tesla MR scannerwith a custom-made external transceive coil;Healthyvolunteer study. J Magn Reson Imaging 25:517-526, 2007.

10) Scheenen, T.W., Heijmink, S.W., Roell, S.A., et al.:Threedimensionalproton MR spectroscopy of human prostate at 3T without endorectal coil;Feasibility. Radiology 245:507-516, 2007.
pubmed

11) Choi, H., Ma, J.:Use of perfluorocarbon compound in theendorectal coil to improve MR spectroscopy of the prostate.Am J Roentgenol:1055-1059, 2008.

12) Jung, J.A., Coakley, F.V., Vigneron, D.B., et al.:Prostatedepiction at endorectal MR spectroscopic imaging;Investigationof a standardized evaluation system. Radiology 233:701-708, 2004.

13) Mulkern, R.V., Bowers, J.L., Peled, S., et al.:Citrate signalenhancement with a homonuclear J-refocusing modificationto double-echo PRESS sequences. Magn Reson Med 36:775-780, 1996.

14) Scheenen, T.W., Gambarota, G., Weiland, E., et al.:Optimaltiming for in vivo 1H-MR spectroscopic imaging of thehuman prostate at 3T. Magn Reson Med 53:1268-1274,2005.

15) Chen, A.P., Cunningham, C.H., Kurhanewicz, J., et al.:High-resolution 3D MR spectroscopic imaging of the prostateat 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 24:825-832, 2006.

16) Kurhanewicz, J., Vigneron, D.B., Hricak, H., et al:Threedimensional H-1 MR spectroscopic imaging of the in situhuman prostate with high (0.24-0.7cm3) spatial resolution.Radiology 198:795-805, 1996.

17) Weinreb, J.C., Blume, J.D., Coakley, F.V., et al.:Prostatecancer;Sextant localization at MR imaging and MR spectroscopicimaging before prostatectomy--results of ACRIN prospectivemulti-institutional clinicopathologic study. Radiology 251:122-133, 2009.

18) Scheenen, T.W., Weiland, S., Van Hecke, P., et al.:Final Results of IMAPS;An International Multi-Centre Assessmentof Prostate MR Spectroscopy. Proceedings of the 94th Annual Meeting of RSNA (Abstract SSK08-02), 2008.

19) Zakian, K.L., Eberhardt, S., Hricak, H., et al.:Transitionzone prostate cancer;Metabolic characteristics at 1H MRspectroscopic imaging-initial results. Radiology 229:241-247, 2003.

20) Futterer, J.J., Heijmink, S.W., Scheenen, T.W., et al.:Prostatecancer localization with dynamic contrast-enhanced MRimaging and proton MR spectroscopic imaging. Radiology 241:449-458, 2006.

21) Reinsberg, S.A., Payne, G.S., Riches, S.F., et al.:Combineduse of diffusion-weighted MRI and 1H MR spectroscopyto increase accuracy in prostate cancer detection. Am JRoentgenol 188:91-98, 2007.

22) Prando, A., Kurhanewicz, J., Borges, A.P., et al.:Prostaticbiopsy directed with endorectal MR spectroscopic imagingfindings in patients with elevated prostate specific antigenlevels and prior negative biopsy findings;Early experience.Radiology 236:903-910, 2005.

23) Lawrentschuk, N., Fleshner, N.:The role of magnetic resonanceimaging in targeting prostate cancer in patients withprevious negative biopsies and elevated prostate-specificantigen levels. BJU Int 103:730-733, 2009.

24) Mueller-Lisse, U.G., Swanson, M.G., Vigneron, D.B., et al.:Time-dependent effects of hormone-deprivation therapy onprostate metabolism as detected by combined magnetic resonanceimaging and 3D magnetic resonance spectroscopicimaging. Magn Reson Med 46:49-57, 2001.

25) Pucar, D., Shukla-Dave, A., Hricak, H., et al.:Prostatecancer:correlation of MR imaging and MR spectroscopywith pathologic findings after radiation therapy-initial experience. Radiology 236:545-553, 2005.

26) Zakian, K.L., Sircar, K., Hricak, H., et al.:Correlation ofproton MR spectroscopic imaging with Gleason score basedon step-section pathologic analysis after radical prostatectomy. Radiology 234:804-814, 2005.

27) Hom, J.J., Coakley, F.V., Simko, J.P., et al.:High-gradeprostatic intraepithelial neoplasia in patients with prostatecancer;MR and MR spectroscopic imaging features-initialexperience. Radiology 242:483-489, 2007.

28) Shukla-Dave, A., Hricak, H., Ishill, N.M., et al.:Correlationof MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression inprostate cancer. Radiology 250:803-812, 2009.

29) Shukla-Dave, A., Hricak, H., Ishill, N., et al.:Prediction ofprostate cancer recurrence using magnetic resonance imagingand molecular profiles. Clin Cancer Res 15:3842-3849,2009.

30) Westphalen, A.C., Coakley, F.V., Kurhanewicz, J., et al.:Mucinous adenocarcinoma of the prostate;MRI and MRspectroscopy features. Am J Roentgenol 193:W238-243,2009.

31) Shukla-Dave, A., Hricak, H., Eberhardt, S.C., et al.:Chronicprostatitis;MR imaging and H MR spectroscopic imagingfindings-initial observations. Radiology 231:717-724,2004.

32) Prando, A., Billis, A.:Focal prostatic atrophy;Mimicryof prostatic cancer on TRUS and 3D-MRSI studies. Abdom Imaging 34:271-275, 2009.
pubmed

33) Qayyum, A., Coakley, F.V., Lu, Y., et al.:Organ-confinedprostate cancer;Effect of prior transrectal biopsy onendorectal MRI and MR spectroscopic imaging. Am J Roentgenol 183:1079-1083, 2004.

P.253 掲載の参考文献

1) Sijens, P.E., Oudkerk, M., van Dijk, P., et al.:1H MR spectroscopymonitoring of changes in choline peak area and lineshape after Gd-contrast administration. Magn Reson Imaging 16:1273-1280, 1998.

2) Okada, T., Harada, M., Matsuzaki, K., et al.:Evaluation offemale intrapelvic tumors by clinical proton MR spectroscopy.J Magn Reson Imaging 13:912-917, 2001.

3) Booth, S.J., Pickles, M.D., Turnbull L.W.:In vivo magneticresonance spectroscopy of gynaecological tumours at 3.0Tesla. BJOG 116:300-303, 2009.

4) Stanwell, P., Russell, P., Carter, J., et al.:Evaluation ofovarian tumors by proton magnetic resonance spectroscopyat three Tesla. Invest Radiol 43:745-751, 2008.

5) Takeuchi, M., Matsuzaki, K., Harada, M., et al.:MR Imaging and MR Spectroscopy of Female Intra-Pelvic Tumors ; Preliminary Experience at 3.0 Tesla. Proc. Intl Soc Mag Reson Med 13:541, 2005.

6) Takeuchi, M., Matsuzaki, K., Harada, M., et al.:High intensemyometrial tumors on T2-weighted images ; Differentiationwith diffusion-weighted imaging and 1H-MR spectroscopy.Proc Intl Soc Mag Reson Med 17:4142, 2009.

7) Takeuchi, M., Matsuzaki, K., Harada, M.:Differentiation ofbenign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T;Preliminary study. Eur Radiol 21:850-856, 2011.

8) deSouza, N.M., Soutter, W.P., Rustin, G., et al.:Use ofneoadjuvant chemotherapy prior to radical hysterectomy incervical cancer ; Monitoring tumour shrinkage and molecularprofile on magnetic resonance and assessment of 3-year outcome.Br J Cancer 90:2326-2331, 2004.

9) Mahon, M.M., Cox, I.J., Dina, R., et al.:1H magnetic resonancespectroscopy of preinvasive and invasive cervical cancer; In vivo-ex vivo profiles and effect of tumor load. J Magn Reson Imaging 19:356-364, 2004.

10) De Silva, S.S., Payne, G.S., Morgan, V.A., et al.:Epithelialand stromal metabolite changes in the transition from cervicalintraepithelial neoplasia to cervical cancer ; An in vivo 1H magnetic resonance spectroscopic imaging study with exvivo correlation. Eur Radiol 19:2041-2048, 2009.

11) Celik, O., Sarac, K., Hascalik, S., et al.:Magnetic resonancespectroscopy features of uterine leiomyomas. Gynecol Obstet Invest 58:194-201, 2004.

12) Hascalik, S., Celik, O., Sarac, K., et al.:Metabolic changesin pelvic lesions ; Findings at proton MR spectroscopicimaging. Gynecol Obstet Invest 60:121-127, 2005.

13) Delikatny, E.J., Chawla, S., Leung, D.J., et al.:MR-visiblelipids and the tumor microenvironment. NMR Biomed 24:592-611, 2011.
pubmed

14) Takeuchi, M., Matsuzaki, K., Harada, M.:Clinical significance of lipid peak in in-vivo 1H-MR spectroscopy of ovarianthecomas/fibrothecomas. Proc Intl Soc Mag Reson Med 19:2963, 2011.

15) Takeuchi, M., Matsuzaki, K., Harada, M.:Clinical significance of creatine peak in in-vivo 1H-MR spectroscopy ofgynecologic tumors. Proc Intl Soc Mag Reson Med 19:2964,2011.

16) Hascalik, S., Celik, O., Sarac, K., et al.:Clinical significanceof N-acetyl-L-aspartate resonance in ovarian mucinouscystadenoma. Int J Gynecol Cancer 16:423-426, 2006.

17) Andre, E., Xu, M., Yang, D., et al.:MR spectroscopy insinus mucocele ; N-acetyl mimics of brain N-acetylaspartate.AJNR Am J Neuroradiol 27:2210-2213, 2006.

18) Candiota, A.P., Majos, C., Bassols, A., et al.:Assignmentof the 2.03 ppm resonance in in vivo 1H MRS of humanbrain tumour cystic fluid ; Contribution of macromolecules.MAGMA 17:36-46, 2004.

19) Mun. C.W., Cho, J.Y., Shin, W.J., et al.:Ex vivo proton MRspectroscopy (1H-MRS) for evaluation of human gastric carcinoma.Magn Reson Imaging 22:861-870, 2004.

20) Takeuchi, M., Matsuzaki, K., Harada, M, et al.:Clinical significanceof the 2 ppm resonance in in-vivo 1H-MR spectroscopyof ovarian tumors. Proc Intl Soc Mag Reson Med 18:4670, 2010.

21) Takeuchi, M., Matsuzaki, K., Harada, M.:Preliminaryobservations and clinical value of N-acetyl resonances inovarian tumours using in-vivo proton MR spectroscopy at 3T.Eur Radiol 21:2640-2646, 2011.

22) Lee, J.H., Cho, K.S., Kim, Y.M., et al.:Localized in vivo 1H nuclear MR spectroscopy for evaluation of human uterinecervical carcinoma. AJR Am J Roentgenol 170:1279-1282,1998.

23) Garg, M., Gupta, R.K., Husain, M, et al.:Brain abscesses;Eiologic categorization with in vivo proton MR spectroscopy.Radiology 230:519-527, 2004.

P.259 掲載の参考文献

1) ACR Practice guideline for the performance of contrastenhanced magnetic resonance imaging (MRI) of the breast. (www.acr.org/Secondary Main Menu Categories/quality_safety/guidelines/breast.aspx)

2) Mann, R.M., Kuhl, C.K., Kinkel, K., Boetes, C.:Breast MRI;Guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307-1318, 2008.
pubmed

3) Glunde, K., Jie, C., Bhujwalla, Z.M.:Molecular causes ofthe aberrant choline phospholipid metabolism in breast cancer.Cancer Res 64:4270-4276, 2004.

4) Stanwell, P., Gluch, L., Clark, D., et al.:Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5T. Eur Radiol 15:1037-1043, 2005.
pubmed

5) Kvistad, KA., Bakken, IJ., Gribbestad, IS., et al.:Characterizationof neoplastic and normal human breast tissues with invivo 1H MR spectroscopy. J Magn Reson Imaging 10:159-164, 1999.

6) Tozaki, M.:Proton MR spectroscopy of the breast. Breast Cancer 15:218-223, 2008.
pubmed

7) Stanwell, P., Mountford, C.:In vivo proton MR spectroscopyof the breast. Radiographics 27:S253-S266, 2007.

8) Star-Lack, J., Nelson, SJ., Kurhanewicz, J., et al.:Improvedwater and lipid suppression for 3D PRESS CSI using RFband selective inversion with gradient dephasing (BASING) .Magn Reson Med 38:311-321, 1997.
pubmed

9) Bolan, P.J., Meisamy, S., Baker, E.H., et al.:In vivo quantificationof choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 50:1134-1143, 2003.

10) Bakken, I.J., Gribbestad, IS., Singstad, T.E., Kvistad, K.A.:External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MRspectroscopy at 1.5 Tesla. Magn Reson Med 46:189-192,2001.

11) Roebuck, J.R., Cecil, K.M., Schnall, M.D., Lenkinski, R.E.:Human breast lesions:characterization with proton MR spectroscopy.Radiology 209:269-275, 1998.
pubmed

12) Cecil, K.M., Schnall, M.D., Siegelman, E.S., Lenkinski,R.E.:The evaluation of human breast lesions with magneticresonance imaging and proton magnetic resonance spectroscopy.Breast Cancer Res Treat 68:45-54, 2001.

13) Yeung, D.K., Cheung, H.S., Tse, G.M.:Human breastlesions:characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results. Radiology 220:40-46,2001.

14) Jagannathan, N.R., Kumar, M., Seenu, V., et al.:Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapyin locally advanced breast cancer. Br J Cancer 84:1016-1022, 2001.

15) Tse, G.M., Cheung, H.S., Pang, L.M., et al.:Characterization of lesions of the breast with proton MR spectroscopy;Comparison of carcinomas, benign lesions, and phyllodestumors. Am J Roentgenol 181:1267-1272, 2003.

16) Huang, W., Fisher, P.R., Dulaimy, K., Tudorica, L.A., O:Hea, B., Button, T.M.:Detection of breast malignancy;Diagnostic MR protocol for improved specificity. Radiology 232:585-591, 2004.
pubmed

17) Bartella, L., Morris, E.A., Dershaw, D.D., et al.:Proton MR spectroscopy with choline peak as malignancy markerimproves positive predictive value for breast cancer diagnosis;Preliminary study. Radiology 239:686-692, 2006.

18) Sardanelli, F., Fausto, A., Di Leo, G., et al.:In vivo proton MR spectroscopy of the breast using the total choline peakintegral as a marker of malignancy. Am J Roentgenol 192:1608-1617, 2009.

19) Tozaki, M., Fukuma, E.:1H MR spectroscopy and diffusion-weighted imaging of the breast;Are they useful toolsfor characterizing breast lesions before biopsy? Am J Roentgenol 193:840-849, 2009.

20) American College of Radiology. Breast imaging reportingand data system (BI-RADS), fourth ed. Reston, VA:American College of Radiology, 2003.

21) Bartella, L., Thakur, S.B., Morris, E.A., et al.:Enhancingnonmass lesions in the breast;Evaluation with proton (1H) MR spectroscopy. Radiology 245:80-87, 2007.
pubmed

22) 坂本正明, 戸崎光宏, 佐川倫子・他:乳腺血管肉腫の1例. 日臨外会誌, 70 (9), 2633-2636, 2009.

23) Tozaki, M., Kobayashi, T., Uno, S., et al.:Breast-conservingsurgery after chemotherapy;Value of MDCT for determiningtumor distribution and shrinkage pattern. Am J Roentgenol 186:431-439, 2006.

24) Jagannathan, N.R., Kumar, M., Seenu, V., et al.:Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapyin locally advanced breast cancer. Br J Cancer 84:1016-1022, 2001.

25) Meisamy, S., Bolan, P.J., Baker, E.H., et al.:Neoadjuvant chemotherapy of locally advanced breast cancer;Predictingresponse with in vivo 1H MR spectroscopy--a pilot study at 4T. Radiology 233:424-431, 2004.
pubmed

26) Kumar, M., Jagannathan, N.R., Seenu, V., et al.:Monitoring the therapeutic response of locally advanced breastcancer patients;Sequential in vivo proton MR spectroscopystudy. J Magn Reson Imaging 24:325-332, 2006.

27) Manton, D.J., Chaturvedi, A., Hubbard, A., et al.:Neoadjuvant chemotherapy in breast cancer;Early response predictionwith quantitative MR imaging and spectroscopy. Br JCancer 94:427-35, 2006.

28) Tozaki, M., Sakamoto, M., Oyama, Y., et al.:Monitoringof early response to neoadjuvant chemotherapy in breastcancer with 1H MR spectroscopy;Comparison to sequential2-[18F]-fluorodeoxyglucose positron emission tomography. JMagn Reson Imaging 28:420-427, 2008.

29) Baek, H.M., Chen, J.H., Nie, K., et al.:Predicting pathologicresponse to neoadjuvant chemotherapy in breast cancerby using MR imaging and quantitative 1H MR spectroscopy.Radiology 251:653-662, 2009.

30) Tozaki, M.:What is best for early response to chemotherapy:size, curve, diffusion, spectroscopy, PET? Eur Radiol19:S944-946, 2009.

31) Tozaki, M., Oyama, Y., Fukuma, E.:Preliminary study ofearly response to neoadjuvant chemotherapy after the firstcycle in breast cancer;Comparison of 1H MR spectroscopywith diffusion MR imaging. Japanese Journal of Radiology28:101-109, 2010.

32) Tozaki, M., Sakamoto M., Oyama, Y., et al.:Predicting pathological response to neoadjuvant chemotherapy in breastcancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895-902,2010.

33) Rousseau, C., Devillers, A., Sagan, C., et al.:Monitoring ofearly response to neoadjuvant chemotherapy in stage II andIII breast cancer by [18F] fluorodeoxy glucose positron emission tomography. J Clin Oncol 24:5366-5372, 2006.

34) Tozaki, M., Hoshi, K.:1H MR spectroscopy of invasiveductal carcinoma:correlations with 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) and histologicalprognostic factors. Am J Roentgenol 194:1384-1390, 2010.

略語一覧表(本文中は略語のみ記載)

P.264 掲載の参考文献

1) Graaf R.A.D:in vivo NMR Spectroscopy. John Wiley &Sons, Ltd:pp9, 2007.

2) Bluml, S.:In vivo quantification of cerebral metabolite concentrations using natural abundance 13C-MRS at 1.5T.JMR 136:219-225,1999.

3) Henry, P.G., Adriany, G., Deelchand, D., et. al.:In vivo 13CNMR spectroscopy and metabolic modeling in the brain;Apractical perspective. Magn Reson Img 24:527-539, 2006.

4) Harada, M., Kubo, H., Abe, T., et. al.:Selection of endogenous 13C substrates for observation of intracellular metabolismusing the dynamic nuclear polarization (DNP) technique Jpn J Radiol 28 (2):173-179, 2010.

P.268 掲載の参考文献

1) Bottomley, PA.:Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 508:333, 1987.
pubmed

2) Beckmann, N., Seelig, J., Wick, H.:Analysis of glycogenstorage disease by in vivo 13C NMR comparison of normalvolunteers with a patient. Mag Reson Med 16:150, 1990.

3) Kunnecke, B., Kustermann, E., Seelig, J.:Simultaneous invivo monitoring of hepatic glucose and glucose-6-phosphateby 13C-NMR spectroscopy. Mag Reson Med 44:556, 2000.

4) Waugh, JS.:Systematic procedure for constructing broadband decoupling sequence. J Magn Reson 49:517, 1982.

5) Shaka, AJ., Keeler, J., Frenkiel, T., et al.:An improved sequence for broadband decoupling;WALTZ-16. J Magn Reson 52:335, 1983.

6) Freeman, R., Hill, HDW., Kaptein, R.:Proton-decoupled NMR spectra of carbon-13 with the nuclear Overhausereffect suppressed. J Magn Reson 7:327, 1972.

7) Overhauser, AW.:Polarization of nuclei in metals. Phys Rev92:411, 1953.

8) Beckmann, N., Fried, R., Turkalj, I., et al.:Noninvasiveobservation of hepatic glycogen formation in man by 13CMRS after oral and intravenous glucose administration. Mag Reson Med 29:583, 1993.

9) Tomiyasu, M., Obata, T., Nonaka, H., et al.:Evaluatingglycogen signal contamination in muscle by 13C MRS of theliver. Magnetic Resonance Imaging 26:572, 2008.

10) Tomiyasu, M., Obata, T., Nishi, Y., et al.:Monitoring ofliver glycogen synthesis in diabetic parients using carbon-13MR spectroscopy. Euro J Radiol 73:300-304, 2010.

11) Ross, B., Lin, A., Harris, K., et al.:Clinical experience with 13C MRS in vivo . NMR in Biomedicine 16:358, 2003.
pubmed

12) Li, S., Yang, J., Shen, J.:Novel strategy for cerebral 13C MRS using very low RF power for proton decoupling. Mag Reson Med 57:265, 2007.

13) Rothman, DL., Magnusson, I., Katz, LD., et al.:Quantitation of hepatic glycogenolysis and glyconeogenesis in fastinghumans with 13C NMR. Science 254:573, 1991.

14) Magnusson, I., Rothman, DL., Katz, LD., et al.:Increasedrate of glyconeogenesis in type II diabetes mellitus. J Clin Invest 90:1323, 1992.

15) Taylor, R., Magnusson, I., Rothman, DL., et al.:Direct assessment of liver glycogen storage by 13C nuclear magneticresonance spectroscopy and regulation of glucose homeostasisafter a mixed meal in normal subjects. J Clin Invest 97:126, 1996.

16) Ikehira, H., Obata, T., Koga, M., et al.:Human hepatic carbohydratemetabolism;Dynamic observation using 13C MRSwithout proton decoupling. Acta Radiol 38:998, 1997.

17) Krssak, M., Brehm, A., Bernroider, E., et al.:Alterations inpostprandial hepatic glycogen metabolism in type 2 diabetes.Diabetes 53:3048, 2004.
pubmed

18) Hwang, JH., Perseghin, G., Rothman, DL., et al.:Impairednet hepatic glycogen synthesis in insulin-dependent diabeticsubjects during mixed meal ingestion;A 13C nuclear magneticresonance spectroscopy study. J Clin Invest 95:783,1995.

19) Cline, GW., Rothman, DL., Magnusson, I., et al.:13C-nuclearmagnetic resonance spectroscopy studies of hepaticglucose metabolism in normal subjects and subjects withinsulin-dependent mellitus. J Clin Invest 94:2369, 1994.

20) Pertersen, KF., Krssak, M., Navarro, V., et al.:Contributionsof net hepatic glycogenolysis and gluconeogenesis toglucose production in cirrhosis. Am J Physiol 276:E529,1999.

21) Roser, W., Beckmann, N., Wiesmann, U., et al.:Absolutequantification of the hepetic glycogen content in a patientwith glycogen storage disease by 13C magnetic resonancespectroscopy. Magn Reson Imag 14:1217, 1996.

22) Thomas, EL., Frost, G., Barnard, ML., et al.:An in vivo 13C magnetic resonance spectroscopic study of the relationshipbetween diet and adipose tissue composition. Lipids 31:145, 1996.

23) Hwang, JH., Bluml, S., Leaf, A., et al.:In vivo characterizationof fatty acids in human adipose tissue using naturalabundance 1H decoupled 13C MRS at 1.5 T;Clinical applicationstodietary therapy. NMR in Biomedicine 16:160,2003.

P.271 掲載の参考文献

1) 放射線医療技術叢書 (18) MR撮像技術 2.1MR信号とMRS技術. 88-111, 2000.

2) Graaf, R.A.D.:in vivo NMR Spectroscopy. John Wiley &Sons, Ltd 81, 2007.

3) Otuka, H., Harada, M., Koga, K., et al.:Effects of hepaticimpairment on the metabolism of fructose and 5-fluorouracil,as studied in fatty liver models using in vivo 31P-MRS and F-MRS. Magn Reson Imaging 17:283-290, 1999.

4) Waters, E.A., Chen, J., Allen, J.S., et al.:Detection and quantification of angiogenesis in experimental valve diseasewith integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson 10:43, 2008.

5) Menon, D.K., Lockwood, G.G., Peden, C.J., et al.:In vivo fluorine-19 magnetic resonance spectroscopy of cerebralhalothane in postoperative patients:preliminary results. Magn Resona Med 30:680-684, 1993.

6) Harada, M., Koga, K., Miura, I., et al.:A new methods for the evaluation of the liver injury by 19F MRS of 5-fluorouracil.Magn Reson Med 22:499-504, 1991.
pubmed

7) Seddon, B.M., Payne, G.S., Simmons, L., et al.:A phase Istudy of SR-4554 via intravenous administration for noninvasiceinvestigation of tumor hypoxia by magnetic resonancespectroscopy in patients with malignancy. Clin Cancer Res 9:5101-5112, 2003.

8) Lee, C.P., Payne, G.S., Oregioni, A., et al.:A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magneticresonane spectroscopy. Br J Caner 101:1860-1868,2009.

9) Mancini, L., Davies, L., Friedlos, F., et al.:A novel techniqueto monitor carboxypeptidase G2 expression in suicidegene therapy using 19F magnetic resonance spectroscopy.NMR Biomed 22:561-566, 2009.

10) Neubauer, A.M., Myerson, J., Caruthers, S.D., et al.:Gadolinium-modulated 19F signals from perfluorocarbon nanoparticlesas a new strategy for molecular imaging. Magn Reson Med 60:1066-1072, 2008.

11) Eleff, S.M., Mclennan, I.J., Hart, G.K., et al.:Shift reagent enhanced concurrent 23Na and 1H magnetic resonance spectroscopic studies of transcellular sodium distribution in thedog brain in vivo . Magn Reson Med 30:11-17, 1993.

12) Shinar, H., Navon, G.:Multinuclear NMR and microscopic MRI studies of the articular cartilage nanostructure. NMRBiomed 19:877-893, 2006.

13) Goodman, J., Neil, J.J., Ackerman, J.J.:Biomedical applicationsof 133Cs NMR. NMR Biomed 18:125-134, 2005.

P.277 掲載の参考文献

1) Jeener, J., Meier, B.H., Bachmann, P., Ernst, R.R.:Investigationof exchange processes by two-dimensional NMR spectroscopy.J Chem Phys 71:4546-4569, 1979.

2) Ernst, R.R., Bodenhausen, G., Wokaun. A.:「2次元NMR-原理と測定法 (永山国昭, 藤原敏道, 内藤晶, 赤坂一之訳) 」, 吉岡書店, 1991.

3) Shriver, J.:Product operators and coherence transfer inmultiple-pulse NMR experiments. Concepts in Magnetic Resonance 4:1-33, 1992.

4) Thomas, M.A., Yue, J., Binesh, N., Davanzo, P., Kumar, A.,Siegel, B., Frye, M., Curran, J., Lufkin, R., Martin, P., Guze.B.:Localized two-dimensional shift correlated MR spectroscopyof human brain. Magn Reson Med 46:58-67 ,2001.

5) Thomas, M.A., Hattori, N., Umeda, M., Sawada, T., Naruse,S.:Evaluation of two-dimensional L-COSY and JPRESSusing a 3 T MRI scanner ; From phantoms to human in vivo .NMR Biomed 16:245-251 ,2003.

6) Welch, J.W.R., Bhakoo, K., Dixon, R.M., Styles, P., Sibson,N.R., Balmire, A.M.:in vivo monitoring of rat brain metabolitesduring vigabatrin treatment using localized 2D-COSY.NMR Biomed 16:47-54, 2003.

7) Bodenhausen, G., Freeman, R., Niedermeyer, R., Turner,D.L.:Double Fourier transformation in high-resolution NMR. JMagn Reson 26:133, 1977.

8) Dreher, W., Leibfritz, D.:On the use of two-dimensional-JNMR measurements for in vivo proton MRS ; Measurementof homonuclear decoupled spectra without the need for shortecho times. Magn Reson Med 34:331-337, 1995.

9) Girvin, M.E.:Increased sensitivity of COSY spectra by useof constant-time t1 periods (CT-COSY), J Magn Reson Ser A108:99-102, 1994.

10) Watanabe, H., Takaya, N., Mitsumori, F.:Simultaneous observation of glutamate, γ-aminobutyric acid, and glutaminein human brain at 4.7T using localized two-dimensional constant-time correlation spectroscopy. NMR Biomed 21:519-526, 2008.

11) Dreher, W., Leibfritz, D.:Detection of homonuclear decoupled in vivo proton NMR spectra using constant time chemicalshift encoding; CT-PRESS. Magn Reson Imaging 17:141-150, 1999.

12) Thomas, M.A., Chung, H.K., Middlekauff, H.:Localized two-dimensional 1H magnetic resonance exchange spectroscopy; A preliminary evaluation in human muscle. Magn Reson Med 53:495-502, 2005.
pubmed

13) van Ziji, P.C., Chesnick, A.S., Des Pres, D., Moonen,C.T.W., Ruiz-Cabella, J., van Gelderen, P.:In vivo protonspectroscopy and spectroscopic imaging of {1-13C}-glucoseand its metabolic products. Magn Reson Med 30:544-551,1993.

14) Watanabe, H., Umeda, M., Ishihara, Y., Okamoto, K.,Oshio, K., Kanamatsu, T., Tsukada, Y.:Human brain glucosemetabolism mapping using multislice 2D 1H-13C correlation HSQC spectroscopy, Magn Reson Med 43:491-620, 2000.

15) Watanabe, H., Umeda, M., Ishihara, Y., Okamoto, K., Oda,T., Kanamatsu, T., Tsukada, Y.:Quantitative analysis of in vivo 2D 1H-13C HSQC spectra using complex nonlinear leastsquarescurve-fitting. Proc. Intl. Soc. Mag Reson Med 8:1949, 2000.

P.284 掲載の参考文献

1) 三森文行:1H NMR分光法. NMR医学, 日本磁気共鳴医学会編, 丸善, 215-228, 1991.

2) 三森文行, 渡邉英宏:MRSによる代謝解析. 非侵襲・可視化技術ハンドブック, 小川誠二・上野照剛監, エヌティーエス, 85-96, 2007.

3) Hore, PJ.:Solvent suppression in Fourier transform nuclear magnetic resonance. J Magn Reson 55:283-300, 1983.

4) Morris, G.A., Freeman, R.:Selective excitation in Fouriertransformnuclear magnetic resonance. J Magn Reson 29:433-462, 1978.

5) Rothman, D.L., Behar, K.L., Hetherington, H.P., Shulman,R.G.:Homonuclear 1H double-resonance difference spectroscopy of the rat brain in vivo . Proc Natl Acad Sci USA, 81:6330-6334, 1984.
pubmed

6) Rothman, D.L., Petroff, O.A.C., Behar, K.L., Mattson, R.H.:Localized 1H NMR measurements of γ-aminobutyric acid in human brain in vivo . Proc Natl Acad Sci USA, 90:5662-5666, 1993.

7) Henry, P.G., Dautry, C., Hantraye, P., Bloch, G.:Brain GABA editing without macromolecule contamination. Magn Reson Med 45:517-520, 2001.
pubmed

8) Mesher, M., Merkle, H., Kirsch, J., Garwood, M., Gruetter,R.:Simultaneous in vivo spectral editing and water suppression,NMR Biomed 11:266-272, 1998.

9) Rothman, D.L., Novotny, E.J., Shulman, G.I., Howsenman,A.M., Petroff, O.A.C., Mason, G., Nixon, T., Hanstock, C.C.,Prichard, J.W., Shulman, R.G.:1H[-13C]NMR measurements of [4-13C] glutamate turnover in human brain. Proc Natl Acad Sci USA 89:9603-9606, 1992.

10) Forsen, S., Hoffman, R.A.:Study of moderately rapid chemical exchange reactions by means of nuclear magneticdouble resonance. J Chem Phys 39:2892-2901, 1963.

11) Alger J.R, Shulman, R.G.:NMR studies of enzymaticrates in vitro and in vivo by magnetization transfer. Quat Rev Biopys 17:83-124, 1984.

12) Ren, J., Trokowski, R., Zhang, S., Malloy, C.R., Sherry, D.:Imaging the tissue distribution of glucose in livers using aparacest sensor. Magn Reson Med 60:1047-1055, 2008.

13) van Zijl, P.C.M., Jones, C.K., Ren, J., Malloy, C.R., Sherry,A.D.:MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST) . Proc Natl Acad Sci USA 104:4359-4364, 2007.
pubmed

はじめての方へ

個人／法人会員登録のご案内